Composition for maintaining or improving immune function
Patent Information
- Application Number
- MYPI2025003736
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-23
- Filing Date
- 2023-11-27
- Publication Date
- 2024-06-23
AI Technical Summary
Current methods fail to clearly induce differentiation between inflammatory and anti-inflammatory macrophage phenotypes, making it difficult to control their dual nature and maintain immune homeostasis, and existing compositions do not effectively suppress pyroptosis in immune cells.
A composition containing extracellular vesicles with cardiolipin and/or phosphatidylglycerol comprising 30% or more of the total glycerophospholipid membrane, produced by Bacillus coagulans lilac-01 strain, which suppresses pyroptosis and promotes an anti-inflammatory phenotype in microglia, thereby maintaining immune function.
The composition effectively transforms inflammatory microglia into anti-inflammatory microglia, enhancing immune function and improving immune homeostasis by reducing pyroptosis, as demonstrated by increased viable microglia cell numbers and improved mitochondrial activity.
Smart Images

Figure PI2025003736_DRAWING_001 
Figure PI2025003736_DRAWING_002 
Figure PI2025003736_DRAWING_003
Abstract
Description
Composition for maintaining or improving immune function
[0001] The present invention relates to a composition for maintaining or improving immune function.
[0002] Macrophages are a type of immune cell classified as white blood cells, and are cells of the innate immune system that play a role in the body's defense by first phagocytosing, breaking down, and digesting invading pathogens. In host cells infected with pathogenic microorganisms, anti-inflammatory macrophages (M2 macrophages) are thought to be induced from inflammatory macrophages (M1 macrophages) as the infection progresses.
[0003] M1 macrophages produce inflammatory cytokines such as TNF-α and IL-1β, and promote inflammation by releasing inflammatory mediators such as NO produced by nitric oxide synthase (NOS), which uses L-arginine as a substrate. On the other hand, M2 macrophages are characterized by producing the anti-inflammatory cytokine IL-10 and expressing the enzyme arginase-1, which uses arginine as a substrate, to produce ornithine and repair tissue (Non-Patent Document 1).
[0004] In order to achieve a phenotype that acts protectively on cells, a method for inducing the phenotype of microglia, which are macrophages in the brain, from M1 to M2 has been disclosed (Patent Document 1). Also, a method for inducing M2 macrophages by culturing macrophages in the presence of exosomes released by mesenchymal stem cells has been disclosed (Patent Document 2).
[0005] However, due to differences in L-arginine metabolism between M1 and M2 macrophages and the fact that the cytokines they produce are often mixed, it has been difficult to categorize the processes of inflammation and regeneration simply as M1 / M2. This concept cannot fully explain the dual nature of macrophages (cytotoxicity and tissue repair), and it has not been possible to clearly induce differentiation into M1 and M2 types (Non-Patent Document 2).
[0006] International Publication No. 2018 / 055153 International Publication No. 2020 / 184425
[0007] Kasmi KC. et al. Nat. Immunol. 2008; 9:1399-1406Nahrendorf M. et al. Circ. Res. 2016;119:414-417
[0008] Immune cells, such as macrophages, have two phenotypes: inflammatory and anti-inflammatory, and no method has been established to control these two subtypes. Macrophage phenotypes play an important role not only in the development of inflammation and disease, but also in tissue homeostasis. The purpose of this invention is to maintain bodily homeostasis by controlling the two phenotypes, inflammatory and anti-inflammatory, through the cell death patterns of macrophages and other immune cells.
[0009] In recent years, many reports have been published on programmed cell death called pyroptosis, which is associated with inflammatory responses in immune cells such as macrophages, and the detailed process of this response has been clarified. Pyroptosis was discovered as a form of cell death in macrophages infected with Shigella and other bacteria, and it has been reported to induce an inflammatory response by releasing intracellular components.
[0010] The present inventors discovered that extracellular vesicles with specific characteristics suppress pyroptosis in immune cells such as macrophages and maintain an anti-inflammatory phenotype, leading to the completion of the present invention.
[0011] That is, the present invention provides the compositions listed below.
[0012] [1] A composition for maintaining or improving immune function, comprising an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol account for 30% by mass or more of the total glycerophospholipids constituting the membrane.
[0013] [2] A composition for anti-aging, anti-allergy, gastrointestinal improvement, or homeostasis maintenance, comprising an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol account for 30% by mass or more of the total glycerophospholipids constituting the membrane.
[0014] [3] The daily intake of the extracellular vesicles is 10 9The composition according to [1] or [2], wherein the number of the at least one molecule is 1 or more.
[0015] [4] The composition according to [1] or [2], wherein 50% or more of the cardiolipin (CL) and / or phosphatidylglycerol (PG) have an odd-chain saturated fatty acid acyl group in the side chain.
[0016] [5] The composition according to [1] or [2], wherein the extracellular vesicles have a zeta potential of −10 mV or less in Ca- and Mg-free Dulbecco's phosphate buffered saline (DPBS, hereinafter also referred to as PBS).
[0017] [6] The composition according to [1] or [2], further comprising a composition or a basic gel suspension containing arginine or an arginine-rich peptide or protein.
[0018] [7] The composition according to [1] or [2], wherein the immune dysfunction is a chronic inflammatory disease, a neurodegenerative disease, an autoimmune disease, an autoinflammatory disease, or a type 2 inflammatory disease.
[0019] [8] The composition according to [1] or [2], wherein the extracellular vesicles are extracellular vesicles produced by Bacillus coagulans (Weizmannia coagulans) lilac-01 strain (accession number: NITE P-01102) (hereinafter also referred to as "lilac-01EV").
[0020] It has been revealed that, among the membrane components that make up extracellular vesicles (hereinafter also referred to as EVs), cardiolipin (hereinafter also referred to as CL) and / or phosphatidylglycerol (hereinafter also referred to as PG) exhibit strong cytoprotective effects and transform inflammatory microglia that cause pyroptosis into anti-inflammatory microglia.
[0021] By using the present invention, it is possible to provide a composition for maintaining or improving immune function by converting inflammatory microglia, which exhibit a cytoprotective effect and cause pyroptosis, into anti-inflammatory microglia.
[0022] FIG. 1 is a graph showing the comparison results of the number of viable microglial cells in Test Example 1-1 of Example 1. FIG. 2 is a photographic image showing a micrograph of microglia when EV was added in Test Example 1-2 of Example 1. FIG. 3 is a graph showing the comparison results of the number of viable microglial cells and the number of cells that have taken up amyloid beta in Test Example 1-2 of Example 1. FIG. 4 is a photographic image showing a micrograph of microglia when EV was added in Test Example 1-3 of Example 1. FIG. 5 is a photographic image showing the detection results of "Gasdermin D" and "Gasdermin D N-terminus" in the culture supernatant after the addition of EV in Test Example 1-4 of Example 1. FIG. 6 is an electron microscope image of the nanosite particle size distribution (1) and lilac-01EV (2: 200,000 magnification) in Test Example 2-1 of Example 2, and an electron microscope image of the lilac-01 strain producing lilac-01EV (3: 20,000 magnification). Figure 7 is a graph showing the difference in the effect of lilac-01EV depending on the culture medium and the addition of arginine in Test Example 2-2 of Example 2. Figure 8 is a graph showing the relationship between the number of viable cells and zeta potential for various EVs in Test Example 2-3 of Example 2. Figure 9 is a graph showing the results of the number of viable microglial cells after drying lilac-01EV in Test Example 3-1 of Example 3. Figure 10 is a photograph showing the effect of lilac-01EV on gingivostomatitis in cats in Test Example 3-3 of Example 3. Figure 11 is a graph showing the increase in mitochondrial activity of senescent fibroblasts caused by lilac-01EV in Example 4.
[0023] Immunity is the body's defense system against foreign microorganisms. However, in today's world of hygienic environments, the threat of infectious diseases is compounded by the serious problem of immune abnormalities, where the immune response is excessive. Immunity is a function that organisms have acquired through evolution as a system for detecting external factors such as pathogens, known as PAMPs (pathogen-associated molecular patterns), and is initiated by recognition by pattern recognition receptors (PRRs). However, immunity can be induced not only by external factors such as PAMPs, but also by internal factors such as reactive oxygen species, known as DAMPs (damage-associated molecular patterns).
[0024] While inflammation caused by the activation of immune cells drives the death of pathogens and abnormal cells, inflammation in which damaged host cells attack pathogens by dying themselves also plays an important role. On the other hand, damaged cells continue to release DAMPs, which causes a non-infectious inflammatory response, leading to chronic inflammation.
[0025] Necrosis, an accidental cell death, has been known for a long time, but in 1972, Kerr et al. discovered programmed cell death and named it apoptosis. In necrosis, cellular contents are released outside the cell, triggering an inflammatory response, whereas in apoptosis, cells are fragmented in a non-inflammatory manner and phagocytosed by macrophages before disappearing. Pyroptosis was first reported in 1992 as an inflammatory programmed cell death with characteristics not seen in apoptosis.
[0026] Previous reports have suggested that the evolutionary roots of macrophages lie in the M2 type, which has a wound-healing function, and that the defensive function of M1 macrophages was acquired later in evolution.
[0027] The inventors have conducted research using primary cells of microglia, macrophages in the brain, and have found that inflammation is induced during the process leading to cell death accompanied by cell destruction, resulting in the differentiation of inflammatory (so-called M1) microglia, and that normal microglia under normal conditions exhibit non-inflammatory phagocytic activity and are in an anti-inflammatory (so-called M2) state. In other words, it was found that the inflammatory properties of macrophages are brought about during the process leading to cell death, and that the original form of macrophages is non-inflammatory.
[0028] [Extracellular vesicles] In one embodiment, the composition of the present invention contains an effective amount of extracellular vesicles containing cardiolipin and / or phosphatidylglycerol in a proportion of 30% by mass or more relative to the total glycerophospholipids constituting the phospholipid membrane of the extracellular vesicles.
[0029] Extracellular vesicles are small vesicles with a diameter of about 20 to 500 nm that are released by all cells and are surrounded by the same phospholipid bilayer membrane as the cell membrane. The type of cells that release extracellular vesicles is not limited as long as the effects of the present invention are achieved, but examples include gram-positive bacteria, gram-negative bacteria, fungi, plant cells, animal cells, and archaea. At least one type selected from the group consisting of lactic acid bacteria, soil bacteria, fungi, and plant cells is preferred, and at least one type selected from the group consisting of spore-forming lactic acid bacteria and Clostridium bacteria is more preferred.
[0030] Examples of spore-forming lactic acid bacteria include Bacillus coagulans and Sporolactobacillus inulinus. Bacillus coagulans is commercially available under the name Lacris (registered trademark)-S. In the present invention, the use of Bacillus coagulans species is preferred, and the use of Bacillus coagulans (Weizmannia coagulans) lilac-01 strain is particularly preferred. The lilac-01 strain is described in Japanese Patent No. 5006986 and is deposited at the Patent Microorganisms Depositary Center of the National Institute of Technology and Evaluation under accession number NITE P-1102.
[0031] Examples of Clostridium bacteria include Clostridium butyricum.
[0032] The average particle size of the extracellular vesicles is not limited as long as the effects of the present invention are achieved, but is preferably 20 to 500 nm, more preferably 20 to 400 nm, even more preferably 20 to 300 nm, and even more preferably 20 to 200 nm. In another embodiment, the average particle size of the extracellular vesicles may be, for example, 20 to 150 nm, 20 to 120 nm, 20 to 115 nm, 20 to 110 nm, 20 to 100 nm, 20 to 95 nm, etc.
[0033] Phospholipids in the body are mainly composed of glycerophospholipids, which consist of acidic phospholipids with a net negative charge (cardiolipin CL, phosphatidylglycerol PG, phosphatidic acid PA, phosphatidylserine PS, phosphatidylinositol PI) and neutral phospholipids (phosphatidylcholine PC, phosphatidylethanolamine PE), and EV also basically follows this structure.
[0034] As shown in the examples below, it has been found that, among the membrane components constituting extracellular vesicles, particularly, but not limited to, cardiolipin (CL) and / or phosphatidylglycerol (PG) exhibit a strong cytoprotective effect. In another embodiment of the present invention, it has been shown that a combination of CL and / or PG with phosphatidylserine (PS), phosphatidylinositol (PI), and / or phosphatidic acid (PA) also exhibits a similar protective effect.
[0035] In one embodiment of the present invention, among the glycerophospholipids constituting the membrane of extracellular vesicles, cardiolipin (CL) and / or phosphatidylglycerol (PG) account for 30% by mass or more of the total glycerophospholipids, preferably 40% by mass or more, more preferably 50% by mass or more, even more preferably 60% by mass or more, even more preferably 70% by mass or more, even more preferably 80% by mass or more, particularly preferably 90% by mass or more, and most preferably 95% by mass or more.
[0036] In another embodiment of the present invention, of the glycerophospholipids constituting the membrane of the extracellular vesicles, at least one selected from the group consisting of cardiolipin (CL), phosphatidylglycerol (PG), phosphatidylserine (PS), and phosphatidylinositol (PI), and / or phosphatidic acid (PA) preferably accounts for 30% by mass or more, more preferably 40% by mass or more, even more preferably 50% by mass or more, even more preferably 60% by mass or more, even more preferably 70% by mass or more, even more preferably 80% by mass or more, particularly preferably 90% by mass or more, and most preferably 95% by mass or more, of the total glycerophospholipids.
[0037] In order to suppress pyroptosis in cells, cardiolipin (CL) and / or phosphatidylglycerol (PG) preferably have odd-chain saturated fatty acid acyl groups in their side chains. Specifically, it is preferred that at least 50%, preferably at least 60%, more preferably at least 70%, and even more preferably at least 80% of the cardiolipin (CL) and / or phosphatidylglycerol (PG) have odd-chain saturated fatty acid acyl groups in their side chains. Examples of odd-chain saturated fatty acids include, but are not limited to, at least one selected from the group consisting of pentadecanoic acid (C15:0), heptadecanoic acid (C17:0), undecanoic acid (C11:0), tridecanoic acid (C13:0), nonadecanoic acid (C19:0), heneicosanoic acid (C21:0), tricosanoic acid (C23:0), and pentacosanoic acid (C25:0).
[0038] In another embodiment, cardiolipin (CL) and / or phosphatidylglycerol (PG) may have, for example, 5% or more, preferably 10% or more, more preferably 15% or more, even more preferably 20% or more, even more preferably 25% or more, and even more preferably 30% or more of unsaturated fatty acid acyl groups in their side chains.
[0039] From the viewpoint of exhibiting a significant cytoprotective effect, it is preferable that the extracellular vesicles have a zeta potential that is more negative; for example, in Ca- and Mg-free Dulbecco's phosphate buffered saline (DPBS, manufactured by Sartorius Japan), it is preferable that the extracellular vesicles have a zeta potential of −10 mV or less, more preferably −13 mV or less, even more preferably −14 mV or less, even more preferably −15 mV or less, even more preferably −16 mV or less, even more preferably −17 mV or less, even more preferably −18 mV or less, particularly preferably −19 mV or less, and especially preferably −20 mV or less. Furthermore, the extracellular vesicles may have a zeta potential in Ca- and Mg-free Dulbecco's phosphate buffered saline (DPBS) of, for example, −50 mV or more, −45 mV or more, −40 mV or more, −35 mV or more, −30 mV or more, −28 mV or more, −26 mV or more, or −24 mV or more. The zeta potential of extracellular vesicles in Dulbecco's phosphate buffered saline (DPBS) can be, for example, −50 mV to −10 mV, −40 mV to −10 mV, −30 mV to −10 mV, −28 mV to −10 mV, −24 mV to −10 mV, −50 mV to −13 mV, −40 mV to −13 mV, −30 mV to −13 mV, −28 mV to −13 mV, −24 mV to −13 mV, −50 mV to −14 mV, Examples include 40 mV to -14 mV, -30 mV to -14 mV, -28 mV to -14 mV, -24 mV to -14 mV, -50 mV to -15 mV, -40 mV to -15 mV, -30 mV to -15 mV, -28 mV to -15 mV, -24 mV to -15 mV, -50 mV to -18 mV, -40 mV to -18 mV, -30 mV to -18 mV, -28 mV to -18 mV, and -24 mV to -18 mV.
[0040] From the viewpoint of having a more negative zeta potential, it is preferable that extracellular vesicles coexist with, for example, cationic amino acids. In one embodiment, the composition of the present invention preferably further contains, but is not limited to, a composition containing arginine, an arginine-rich peptide or protein, or a basic gel suspension. The arginine-rich peptide is preferably, but is not limited to, a peptide containing 5 or fewer amino acids, more preferably 2 to 5, and may also contain 3 to 5 or 3 to 4 amino acids. It is also possible to use commercially available products such as, but not limited to, poly-L-arginine (manufactured by Sigma) and oligoarginine (manufactured by Peptide Institute). In another embodiment, the present invention may be a composition for maintaining or improving immune function, anti-aging, anti-allergy, gastrointestinal improvement, or homeostasis, which contains an effective amount of extracellular vesicles having a zeta potential of -10 mV or less in Ca- and Mg-free Dulbecco's phosphate-buffered saline (DPBS).
[0041] Compositions containing an effective amount of the above-mentioned extracellular vesicles can be widely used as foods and drinks, pharmaceuticals, quasi-drugs, cosmetics, feeds, and veterinary medicines.
[0042] The food and drink products are not particularly limited as long as they contain the above-mentioned extracellular vesicles, and examples thereof include soft drinks, carbonated drinks, fruit juice drinks, vegetable juice drinks, fruit and vegetable juice drinks, livestock milk such as cow's milk, soy milk, dairy drinks, drink-type yogurt, drink-type or stick-type jelly, coffee, cocoa, tea drinks, nutritional drinks, energy drinks, sports drinks, infant formula, mineral water, near-water, non-alcoholic beer-flavored drinks with an alcohol content of 1% or less, and other non-alcoholic drinks; carbohydrate-containing foods and drinks such as rice, noodles, bread, and pasta; cheeses, hard Examples of such foods include dairy products such as hard or soft yogurt, fresh cream made from livestock milk or other fats and oils, and ice cream; Western confectioneries such as cookies, cakes, and chocolates; Japanese confectioneries such as buns and yokan; tablet confectioneries (refreshing confectioneries) such as ramune (ramune), candies, chewing gum, gummy candies, frozen desserts and ice creams such as jellies and puddings, and snacks; processed foods using eggs, processed foods (including delicacies) made from seafood or livestock meat (including liver and other offal), and soups such as miso soup; condiments such as miso, soy sauce, furikake (rice seasoning), and other seasonings; and liquid foods such as concentrated liquid foods and enteral nutritional foods. Furthermore, the foods and drinks may be supplements, for example, tablet supplements.
[0043] In the present invention, the dosage form when formulated is not particularly limited, and specific examples include tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, syrups, suppositories, injections, ointments, patches, eye drops, nasal drops, etc. Furthermore, when formulating, additives commonly used as pharmaceutical carriers, such as excipients, binders, disintegrants, lubricants, stabilizers, flavorings, diluents, surfactants, or solvents for injections, can be used.
[0044] The intake amount of the active ingredient of the present invention is not particularly limited and can be determined depending on the sex, age, weight, symptoms, intake time, dosage form, intake route, etc. of the subject. The daily intake amount of the active ingredient of the present invention for an adult can be determined, for example, by the number of extracellular vesicles, and the lower limit thereof is 1 × 10 7 pieces, 1×10 8 pieces, 1×10 9The upper limit is 1 × 10 11 pieces, 1×10 12 pieces, 1×10 13 These upper and lower limits can be arbitrarily combined, and the intake range can be, for example, 1 × 10 7 ~1 x 10 13 pieces, 1×10 8 ~1 x 10 12 pieces, 1×10 9 ~1 x 10 11 The number of extracellular vesicles can be measured, for example, by dynamic light scattering, flow cytometry, or the like.
[0045] [Use] In one embodiment, the composition of the present invention can be used for maintaining or improving immune function.
[0046] The improvement of immune function can be exemplified by improving immune dysfunction, and examples of immune dysfunction include chronic inflammatory diseases, neurodegenerative diseases, autoimmune diseases, autoinflammatory diseases, and type 2 inflammatory diseases. Examples of chronic inflammatory diseases include cellular senescence, arteriosclerosis, and epithelial dysplasia. Examples of neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, prion disease, muscular dystrophy, age-related macular degeneration, and epilepsy. Examples of autoimmune diseases include ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, cataracts, autoimmune kidney disease, and hyperthyroidism. Examples of autoinflammatory diseases include gout, Crohn's disease, and type 2 diabetes. Examples of type 2 inflammatory diseases include asthma, atopic dermatitis, chronic sinusitis, eosinophilic inflammatory syndrome, food allergies, and hay fever.
[0047] In another embodiment, the composition of the present invention can be used for anti-aging, anti-allergy, gastrointestinal tract improvement, or homeostasis maintenance.
[0048] Examples of anti-aging uses include at least one selected from the group consisting of maintaining cognitive function (maintaining memory, attention, concentration, information processing ability, judgment, and executive function), maintaining visual function (improving contrast sensitivity by increasing macular pigment density), maintaining olfactory and auditory functions, maintaining motor function, reducing skin blemishes and wrinkles, reducing skin aging (maintaining moisture and elasticity), reducing hair loss and gray hair, reducing white spots and aging spots, improving skin luster, improving pores, improving hearing, improving gums, improving discomfort in joints such as knees, hips, and fingers (improving joint mobility, maintaining and improving walking ability, and improving finger stiffness), maintaining bone health (maintaining bone density), and improving presbyopia.
[0049] Examples of anti-allergic uses include at least one selected from the group consisting of relief of discomfort in the eyes, nose, and throat, improvement of hay fever, relief of joint pain, relief of food allergies, maintenance of cartilage components, improvement of dry eyes and dry mouth, improvement of food allergies (such as food allergies caused by cross-reactions with pollen), and improvement of discomfort caused by house dust.
[0050] Examples of gastrointestinal improvement agents include at least one selected from the group consisting of improving constipation and diarrhea, regulating stool consistency and shape, relieving postprandial heaviness and heartburn, reducing nausea and bloating, relieving abdominal pain, and reducing gas production.
[0051] For maintaining homeostasis, for example, improvement of liver function (reduction of LDL cholesterol, inhibition of oxidation of LDL cholesterol, reduction of blood AST, ALT, γ-GTP, etc.), alleviation of fatigue and lethargy, alleviation of palpitations, shortness of breath and difficulty in breathing, alleviation of rise in blood sugar level, alleviation of blood sugar spikes, alleviation of rise in blood pressure, improvement of sleep quality (falling asleep, depth of sleep, refreshing awakening), maintenance of skin firmness, improvement of cold hands and feet and body, improvement of swelling, reduction of visceral fat and triglycerides (reduction of body fat, reduction of waist circumference, reduction of BMI), improvement of basal metabolism (improvement of energy consumption, and improved fat burning), maintenance of vascular health, improvement of varicose veins, improvement of smooth muscle tumors, maintenance of mental health, relief of physical discomfort caused by stress, improvement of trembling and itching in the limbs, maintenance of urinary function, maintenance of respiratory function, maintenance of swallowing function, relief of nasal congestion, relief of stomatitis, relief of neuralgia, relief of eye strain, relief of psoriasis, relief of hangovers, relief of dizziness, relief of hot flashes, relief of cold symptoms, hair growth, hair regrowth, myopia, and muscle improvement (maintenance of muscle mass), increase in saliva volume, improvement of bad breath, and reduction of uric acid levels.
[0052] The composition of the present invention can be labeled with the above uses, but is not limited to these uses. It can also be labeled with other uses as long as they express effects that are secondary to the effects of the present invention.
[0053] The term "labeling" as used herein refers to any act intended to inform consumers of the intended use. Any labeling that can conjure up or infer the intended use falls under the category of "labeling" in this specification, regardless of the purpose, content, object, or medium of labeling. However, labeling in a manner that allows consumers to directly recognize the intended use is preferred. Specifically, examples include labeling the intended use on the food and beverage product or its packaging; transferring, delivering, displaying for transfer or delivery, exporting, or importing the product or its packaging on which the intended use is labeled; displaying or distributing the intended use in product advertisements, price lists, or transaction documents; or providing the intended use in information containing the above via electromagnetic means (e.g., the Internet). Labeling on packaging, containers, sales promotion materials such as catalogs, pamphlets, and POP displays, as well as other documents, is particularly preferred.
[0054] Examples of such labels include labeling as health foods, functional foods, enteral nutritional foods, foods for special dietary uses, foods with nutrient functions, and quasi-drugs, as well as other labels approved by the Ministry of Health, Labor and Welfare or the Consumer Affairs Agency, such as labels for specified health uses, foods with functional claims, and labels approved under similar systems. Examples of the latter include labels for specified health uses, labels for conditional specified health uses, labels indicating an effect on the structure or function of the body, and labeling for disease risk reduction. More specifically, examples include labels for specified health uses (particularly labels for health uses) as defined in the Enforcement Regulations of the Health Promotion Act (Ministry of Health, Labor and Welfare Ordinance No. 86 of April 30, 2003), and similar labels.
[0055] Examples of feed include pet food, livestock feed, and fish feed. Such feed can be produced by mixing the composition of the present invention with common feed, such as grains, cereals, bran, fish meal, bone meal, oils and fats, skim milk powder, whey, mineral feed, or yeast. The produced feed can be orally administered to common mammals, livestock, farmed fish, and pets. Veterinary pharmaceuticals can be administered to mammals, livestock, farmed fish, and pets by transdermal administration, eye drops, oral administration, application, inhalation, and the like.
[0056] When the present invention is used as a feed or the like, the target organism is not particularly limited, but is preferably a mammal other than humans, such as a platypus, echidna, opossum, quoll, kangaroo, aardvark, rock badger, elephant, armadillo, sloth, anteater, tree shrew, flying lemur, chimpanzee, rabbit, mouse, hedgehog, camel, wild boar, giraffe, deer, cow, goat, hippopotamus, whale, dolphin, horse, rhinoceros, tapir, bat, tiger, wolf, weasel, bear, seal, dog, or cat, more preferably a dog or cat.
[0057] When the present invention is used as a feed or pet food, it may be given to a pet in divided doses several times a day by adding it to the staple food, or it may be given to a pet as a snack at any time.
[0058] When the present invention is used as feed, pet food, or the like, the oral intake or administration amount of the active ingredient of the present invention per day can be determined, for example, by the number of extracellular vesicles, and is 1 x 10 5 ~1 x 10 12 pieces / kg weight, 1×10 6 ~1 x 10 11 pieces / kg weight, 1×10 7 ~1 x 10 10 The content of the active ingredient of the present invention can be an amount that corresponds to the above-mentioned intake amount or administration amount.
[0059] The present invention can also be embodied in the following manner. a composition for maintaining or improving immune function, comprising an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more relative to the total glycerophospholipids constituting the membrane; a composition for anti-aging, anti-allergic, gastrointestinal tract improvement, or homeostasis maintenance, comprising an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more relative to the total glycerophospholipids constituting the membrane; use of a composition containing an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more relative to the total glycerophospholipids constituting the membrane, for the production of an agent for maintaining or improving immune function; use of a composition containing an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more relative to the total glycerophospholipids constituting the membrane, for the production of an agent for anti-aging, anti-allergic, gastrointestinal tract improvement, or homeostasis maintenance; A method for maintaining or improving immune function, comprising having a subject ingest a composition containing an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more of the total glycerophospholipids constituting the membrane; A method for anti-aging, anti-allergy, gastrointestinal tract improvement, or homeostasis maintenance, comprising having a subject ingest a composition containing an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more of the total glycerophospholipids constituting the membrane; Extracellular vesicles for use in maintaining or improving immune function, in which cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more of the total glycerophospholipids constituting the membrane; Extracellular vesicles for use in anti-aging, anti-allergy, gastrointestinal tract improvement, or homeostasis maintenance, wherein the cardiolipin and / or phosphatidylglycerol accounts for 30% by mass or more of the total glycerophospholipids constituting the membrane of the extracellular vesicles; 9 the composition, use, method, or extracellular vesicle, wherein the daily intake of the extracellular vesicles is 1 x 10 or more; 9 ~1 x 1013the composition, use, method, or extracellular vesicle, wherein 50% or more of the cardiolipin (CL) and / or phosphatidylglycerol (PG) have an odd-chain saturated fatty acid acyl group in the side chain; the composition, use, method, or extracellular vesicle, wherein the odd-chain saturated fatty acid is at least one selected from the group consisting of pentadecanoic acid (C15:0), heptadecanoic acid (C17:0), undecanoic acid (C11:0), tridecanoic acid (C13:0), nonadecanoic acid (C19:0), heneicosanoic acid (C21:0), tricosanoic acid (C23:0), and pentacosanoic acid (C25:0); The composition, use, method, or extracellular vesicles, wherein the extracellular vesicles have a zeta potential of -10 mV or less in Ca- and Mg-free Dulbecco's phosphate buffered saline (DPBS, hereinafter also referred to as PBS); the composition, use, method, or extracellular vesicles, wherein the extracellular vesicles have a zeta potential of -50 mV to -10 mV in Ca- and Mg-free Dulbecco's phosphate buffered saline (DPBS, hereinafter also referred to as PBS); the composition, use, method, or extracellular vesicles, wherein the composition, use, method, or extracellular vesicles further comprises a composition or basic gel suspension containing arginine or an arginine-rich peptide or protein; the composition, use, method, or extracellular vesicles, wherein the immune dysfunction is a chronic inflammatory disease, a neurodegenerative disease, an autoimmune disease, an autoinflammatory disease, or a type 2 inflammatory disease; the extracellular vesicles are derived from Bacillus coagulans the composition, use, method, or extracellular vesicles, wherein the extracellular vesicles are extracellular vesicles (hereinafter also referred to as "lilac-01EV") produced by Weizmannia coagulans lilac-01 strain (accession number: NITE P-01102); the composition, use, method, or extracellular vesicles, wherein the average particle diameter of the extracellular vesicles is 20 to 500 nm; the composition, use, method, or extracellular vesicles, wherein the average particle diameter of the extracellular vesicles is 20 to 200 nm;The composition, use, method, or extracellular vesicle, wherein the extracellular vesicles further contain phosphatidylserine (PS), and / or phosphatidylinositol (PI), and / or phosphatidic acid (PA) in addition to the glycerophospholipids constituting the membrane of the extracellular vesicles; The composition, use, method, or extracellular vesicle, wherein, among the glycerophospholipids constituting the membrane of the extracellular vesicles, cardiolipin (CL) and / or phosphatidylglycerol (PG) accounts for 90% by mass or more of the total glycerophospholipids; the composition, use, method, or extracellular vesicles, wherein the anti-aging effect is at least one selected from the group consisting of maintaining cognitive function (maintaining memory, attention, concentration, information processing ability, judgment, and executive function), maintaining visual function (improving contrast sensitivity by increasing macular pigment density), maintaining olfactory and auditory functions, maintaining motor function, reducing skin blemishes and wrinkles, reducing skin aging (maintaining moisture and elasticity), reducing hair loss and gray hair, reducing white spots and aging spots, improving skin luster, improving pores, improving hearing, improving gums, improving discomfort in joints such as knees, hips, and fingers (improving joint mobility, maintaining and improving walking ability, and improving finger stiffness), maintaining bone health (maintaining bone density), and improving presbyopia; the composition, use, method, or extracellular vesicles, wherein the anti-allergic effect is at least one selected from the group consisting of relief of discomfort in the eyes, nose, and throat, improvement of hay fever, relief of joint pain, relief of food hypersensitivity, maintenance of cartilage components, improvement of dry eyes and dry mouth, improvement of food allergies (such as food allergies due to cross-reactions with pollen), and improvement of discomfort caused by house dust; the composition, use, method, or extracellular vesicles, wherein the gastrointestinal improvement is at least one selected from the group consisting of improvement of constipation and diarrhea, adjustment of stool consistency and shape, relief of postprandial heaviness and heartburn, relief of nausea and vomiting, relief of bloating, relief of abdominal pain, and reduction of gas production;The maintenance of homeostasis is effective in improving liver function (reduction of LDL cholesterol, inhibition of oxidation of LDL cholesterol, reduction of blood AST, ALT, γ-GTP, etc.), alleviating fatigue and lethargy, alleviating palpitations, shortness of breath and difficulty in breathing, alleviating rise in blood sugar levels, alleviating blood sugar spikes, alleviating rise in blood pressure, improving sleep quality (falling asleep, depth of sleep, waking up refreshed), maintaining firm skin, improving coldness of the hands and feet and body, improving swelling, reducing visceral fat and triglycerides (reducing body fat, reducing waist circumference, reducing BMI), improving basal metabolism (improving energy consumption, improving fat burning), and improving blood sugar. the composition, use, method, or extracellular vesicle, wherein the effect is at least one selected from the group consisting of maintaining vascular health, improving varicose veins, improving smooth muscle tumors, maintaining mental health, alleviating physical discomfort caused by stress, improving tremors and itching in the limbs, maintaining urinary function, maintaining respiratory function, maintaining swallowing function, as well as reducing nasal congestion, stomatitis, neuralgia, eye strain, psoriasis, hangover relief, dizziness, hot flashes, cold symptoms, hair growth, hair regrowth, myopia, muscle improvement (maintenance of muscle mass), increasing saliva volume, improving bad breath, and reducing uric acid levels; the method, wherein the subject is a human or a mammal other than a human;
[0060] [1] Evaluation Method and Evaluation Contents The evaluation method and evaluation content of pyroptosis will be described below.
[0061] [1-1] Establishment of a method for evaluating cytoprotective effects using pyroptosis in primary microglia Microglia can be sampled in large quantities in a sterile environment, making them easy to evaluate, and unlike immortalized cells, primary cells exhibit moderate pyroptosis, making them suitable for observing pyroptosis. In the Examples described below, dead microglia were isolated by taking advantage of differences in adhesiveness to culture vessels, and primary microglial cells were prepared and used to evaluate lifespan.
[0062] Primary microglial cells undergo cell death by pyroptosis over time due to contact stimuli with the test container, but the inventors found that the lifespan of primary microglial cells changes when extracellular vesicles (EVs) produced by bacteria are added. The lifespan extension effect is the protective effect from pyroptosis by the added EVs, and the number of surviving cells after a certain period of time represents the biological activity of the EVs, i.e., their cytoprotective effect (Example 1).
[0063] [1-2] Measurement of microglial cell protective effect The inventors seeded primary microglia collected from rat brains and amyloid beta on a 96-well plate and confirmed that the presence or absence of amyloid beta had no short-term effect on microglial cell death, and that pyroptosis progressed over time (Example 1).
[0064] When primary microglia were treated with Escherichia coli-derived EV (ECEV), Lactobacillus paracasei-derived EV (LBEV), and lilac-01EV, significant differences were observed in the rate of pyroptosis in primary microglia (rat) (Example 1).
[0065] The evaluation results showed that the order of the protective effect on microglia cells was lilac-01EV > lactic acid bacteria-derived EV (LBEV) > control (PBS) > Escherichia coli-derived EV (ECEV).
[0066] These studies demonstrated that microglia were strongly protected by EVs. The protective effect of lilac-01EV was particularly strong. Amyloid beta and inflammatory responses were not affected in the short term (Example 1).
[0067] Lipopolysaccharide (LPS) is present in the cell membrane of E. coli and is also expressed in E. coli-derived EVs. LPS is known to stimulate Toll-like receptors (TLRs) on host cells, causing inflammation.
[0068] When E. coli-derived EVs were added to primary microglia pre-treated with lilac-01EV, they showed a longer lifespan than untreated cells (Example 1). This experimental example demonstrates that the protective effect of lilac-01EV was retained, protecting the cells from the toxicity of E. coli-derived EVs. Furthermore, when the GSDRM D N-terminus was detected using culture supernatants of microglial cells supplemented with lilac-01EV and E. coli-derived EVs, the GSDRM D N-terminus was detected only in the supernatant supplemented with E. coli-derived EVs. This confirmed that pyroptosis did not occur with lilac-01EV. Furthermore, it was confirmed that the cytoprotective effect of lilac-01EV was maintained even after drying (Example 3).
[0069] [1-3] Relationship between cytoprotective effect and zeta potential In evaluating the protective effect on primary rat microglia, the inventors found that there is a strong correlation between the protective effect on microglia of the test sample and the zeta potential (R 2 = 0.95, Example 2).
[0070] Microglial cell membranes are negatively charged, and it was shown that the greater the negative zeta potential of the evaluation sample, the stronger the protective effect. It was also found that adding cationic amino acids such as arginine to a solution (culture medium) containing EV further reduced the negative zeta potential, thereby enhancing the protective effect (Example 2).
[0071] It has generally been reported that EVs (outer membrane vesicles) produced by Gram-positive bacteria are anti-inflammatory, while EVs (outer membrane vesicles) produced by Gram-negative bacteria are pro-inflammatory. However, when evaluating the lifespan extension effect of primary microglia, it was found that this tendency was not necessarily observed depending on whether the bacteria were Gram-positive or Gram-negative, and that there was a strong correlation with the zeta potential. Based on this, the inventors discovered that EVs with a stronger negative zeta potential have a stronger cytoprotective effect.
[0072] As mentioned above, EVs are small vesicles with a diameter of approximately 100 nm that are released by all cells and are surrounded by a phospholipid bilayer similar to the cell membrane. Biological phospholipids are composed of acidic phospholipids with a net negative charge (phosphatidylglycerol PG, phosphatidic acid PA, etc.) and neutral phospholipids (phosphatidylcholine PC, phosphatidylethanolamine PE), and EVs essentially share this structure.
[0073] EVs released from ingested food or intestinal bacteria are believed to be taken up by intestinal epithelial cells by macropinocytosis (pinocytosis), but the details of this process are unknown. Liposomes, which are artificial phospholipid vesicles, tend to use cationic liposomes because negatively charged acidic phospholipids cannot penetrate the cell surface. However, positively charged liposomes are generally cytotoxic, and it is known that cells that penetrate them die within a short period of time.
[0074] [1-4] Relationship between cell membrane composition and zeta potential The inventors confirmed that the zeta potential varies depending on the membrane composition of EV. When the glycerophospholipid membrane composition of lilac-01EV was measured, it was found that 30% to 100% by mass of CL or PG was present.
[0075] The acidic phospholipids CL and PG have a strong negative charge, and it was thought that delivering EVs containing CL and PG in their membrane composition to microglia strengthens the negative membrane potential of the microglial cell membrane.
[0076] [1-5] Improvement of intracellular transport by formation of a counterion condensed layer It was shown that the protective effect on microglia (bioactivity) and zeta potential (negative) were enhanced with increasing arginine concentration in the EV medium (Example 2).
[0077] Since the biological activity of EVs increases as the zeta potential becomes lower (more negative), it is thought that positively charged arginine is strongly attracted to the negative potential of EVs, forming a counterion condensation layer around the EVs and approaching the cell membrane of microglia, thereby allowing efficient uptake into the cells.
[0078] Lilac-01EV is mainly composed of CL or PG, which have a negative potential, and can form a counterion condensation layer of arginine-rich positive ions, which have a positive potential. In addition, by increasing the positive ion concentration, a stable counterion condensation layer can be formed. The positive ion layer is composed of Na + Although a counterion condensation layer can be formed with metal ions such as arginine, arginine often causes cell damage when taken up by cells. Although arginine is a positive ion, it is consumed by arginase-1 and other enzymes when taken up by cells, so it does not cause cell damage.
[0079] [1-6] Enhancement of mitochondrial activity by lilac-01EV We added lilac-01EV to senescent fibroblasts for 21 days, and measured the mitochondrial membrane potential on the 22nd day. This confirmed that mitochondrial activity was enhanced (Example 4). We also confirmed that the morphology of senescent fibroblasts was rejuvenated.
[0080] [1-7] Anti-inflammatory effects of odd-chain saturated fatty acids The odd-chain saturated fatty acids (OCFA), pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0), account for approximately 0.2% and 0.4% of total lipids in human plasma phospholipids, respectively. Numerous studies have shown that dietary OCFA are associated with a reduced risk of obesity, chronic inflammation, cardiovascular disease, metabolic syndrome, type 2 diabetes, nonalcoholic steatohepatitis, chronic obstructive pulmonary disease, pancreatic cancer, and other diseases.
[0081] Normally, fatty acids have chain lengths that are extended in units of two carbon atoms, resulting in an even number, but OCFAs are produced by bacteria and protozoa in ruminants, and humans are thought to ingest OCFAs through dairy products and fermented foods.
[0082] OCFA has a lower melting point than even-chain fatty acids, and is therefore reported to have advantages such as high fluidity in cell membranes, high membrane density, and high cell rigidity.
[0083] The cell membrane of lilac-01EV is composed mostly of phospholipids with OCFA in the side chain. After absorption, lilac-01EV can reach mitochondria, where it is thought that OCFA is released after being replaced by unsaturated fatty acids such as linoleic acid through remodeling. This allows OCFA to be delivered to mitochondria more efficiently than OCFA ingested through food.
[0084] [1-8] Effects of phospholipids other than CL and PG The cell membrane of lilac-01EV is composed almost entirely of CL or PG. However, by changing the culture conditions of Bacillus coagulans (Weissmannia coagulans) lilac-01, it is possible to introduce other phospholipids into lilac-01EV.
[0085] Phosphatidic acid (PA) is produced from glycerol 3-phosphate (G3P) by the action of bacterial diacylglycerol kinase. PA is the starting material for all glycerophospholipids, and from PA, phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), etc. can be synthesized via diacylglycerol (DAG).
[0086] In general, PE is the major phospholipid in bacteria, and PE is ubiquitously present in the cell membranes of prokaryotes and eukaryotes. By culturing Bacillus coagulans (Weissmannia coagulans) lilac-01 in a culture medium containing ethanolamine, for example by co-culturing with other cells, phosphatidylethanolamine (PE) can be introduced into EVs.
[0087] Similarly, in a culture medium containing serine, or / and choline, or / and inositol, phosphatidylserine (PS), or / and phosphatidylcholine (PC), or / and phosphatidylinositol (PI) can be introduced into EVs.
[0088] Like CL and PG, PS and PI are negatively charged phospholipids that are normally present on the inner side of the lipid bilayer that makes up the cell membrane and the outer mitochondrial membrane. Like CL, their fatty acid side chains are easily oxidized, and when attacked by gasdermins, they form holes in the cell membrane, inducing pyroptosis.
[0089] When PS or PI was introduced into lilac-01EV, it is thought that they would not be attacked by gasdermin because they lack unsaturated fatty acids. However, after remodeling, they would contain unsaturated fatty acids, which would lead to the formation of pores in the outer mitochondrial membrane, releasing cytochrome c and inducing apoptosis.
[0090] Scrambling of the cell membrane occurs, exposing PS to the outside of the lipid bilayer, which allows the cells to be phagocytosed by macrophages in a non-inflammatory manner (eat me sign).
[0091] Introducing PS or PI into lilac-01EV is expected to suppress pyroptosis, while introducing PS is expected to promote apoptosis. PI also plays an important role in intercellular signaling through enzymatic phosphorylation, and is known to be particularly involved in the growth of neuronal dendrites, axonal elongation, and synapse formation. Introducing PI into lilac-01EV is expected to have effects such as improving dementia.
[0092] PC and PE are neutrally charged, and their introduction into lilac-01EVs does not inhibit apoptosis or pyroptosis. PC is primarily located on the outer surface of the cell membrane and serves as an important source of choline. It is also known that PC crosses the blood-brain barrier and is taken up into the brain and used to build neurons. Acetylcholine is synthesized by the enzyme choline acetyltransferase, and acetylcholine functions as a transmitter in motor nerve endings, sympathetic and parasympathetic ganglia, parasympathetic nerve endings, and sympathetic nerve endings. EVs containing PC are expected to be selectively delivered to these sites where acetylcholine receptors are present. Specifically, they are expected to improve cognitive function, stimulate gastrointestinal activity, regulate heart rate, and reduce intraocular pressure in various parts of the brain, heart, smooth muscle, and eyes.
[0093] PE, together with CL, enhances the stability of the inner mitochondrial membrane. It is also important for the construction of intracellular organelles in animal cells and is an essential component for the regulation of vesicular transport and endocytosis (the process of eating).
[0094] Lilac-01EV can incorporate various phospholipids, and the effects of the present invention are effective when the composition ratio of CL and / or PG relative to the total glycerophospholipids is 30% by mass or more, preferably 40% by mass or more, more preferably 50% by mass or more, and most preferably 60% by mass or more. Furthermore, by further incorporating negatively charged phospholipids PI and / or PS, or neutral phospholipids PC and / or PE, it becomes possible to deliver the respective components into cells and mitochondria.
[0095] [2] Presumed Mechanism of Action of the Present Invention The presumed mechanism of action of the present invention will now be described, although it is not limited thereto.
[0096] [2-1] Why lowering the membrane potential extends cell lifespan It has become clear that the lipid bilayer membranes of living organisms not only maintain cell structure and control the movement of substances in and out of cells, but are also involved in various forms of intercellular information transmission.
[0097] CL is a structure in which PG2 molecules are associated, and is a negatively charged phospholipid that is specifically present in mitochondria in animal cells. Mitochondria consist of two lipid bilayers, an outer membrane and an inner membrane, and the inner mitochondrial membrane in particular exhibits a strong negative potential because 80-90% by mass of CL is present. This negative potential is H + Ions are attracted to the mitochondrial membrane to form a mitochondrial membrane potential, and hydrogen ions are further pumped out by the proton pump present in the inner mitochondrial membrane, causing the membrane potential to reach a maximum of -180 mV.
[0098] Mitochondria are H + ATP, the source of life activity, is produced by ion concentration gradients, and loss of membrane potential (depolarization) can cause mitochondrial dysfunction and cell death.
[0099] Similarly, bacteria also use the negative potential of acidic phospholipids as a foothold to + ATP is synthesized by the cell membrane potential based on the ion concentration gradient, but in the case of bacteria, the efficiency decreases as the cell size increases because the surface area ratio decreases.
[0100] It is believed that eukaryotes began their evolutionary journey by adopting mitochondria, which originated from bacteria, as endosymbiotic cells. Mitochondria are characterized by their inner membrane surface area and negative membrane potential. The importance of this negative membrane potential for maintaining mitochondrial function has not previously been emphasized, but experiments conducted by the inventors have revealed that loss of biomembrane potential can lead to cell death.
[0101] [2-2] Function of CL / PG CL has a cone shape with four fatty acyl groups and a negatively charged head that can capture positive charges. This unique structure determines the basic function of mitochondria. Mitochondria are intracellular organelles, each containing hundreds to thousands of mitochondria, and are highly dynamic organelles that repeatedly divide and fuse. CL is a phospholipid essential for this mitochondrial dynamics, and it fuses mitochondria that have become dysfunctional due to factors such as loss of membrane potential (depolarization) with highly active mitochondria, and further divides them to disperse damage and maintain mitochondrial activity.
[0102] Mitochondrial inner membranes have a unique structure (cristae) that increases their surface area and maximizes ATP production. CLs are known to be essential for maintaining this cristae structure and mitochondrial function, and conical CLs are thought to be particularly necessary to form highly curved surfaces.
[0103] Furthermore, mitochondria are the largest source of reactive oxygen species (ROS) in the body, and when ROS production increases due to insufficient ROS scavenging mechanisms, the divided mitochondria are decomposed by selective autophagy (mitophagy). Furthermore, when mitophagy stagnates and dysfunctional mitochondria increase, the mitochondria eliminate the cell itself through apoptosis.
[0104] [2-3] Mechanism of cell death Apoptosis is a non-inflammatory programmed cell death that is initiated by the action of BCL-2-related proteins, which form pores in the outer mitochondrial membrane, causing cytochrome c (a key protein in the electron transport chain) to escape through these pores into the cytoplasm.
[0105] Caspase-dependent pyroptosis is also associated with mitochondrial perforation. Pyroptosis is a cell death mode characterized by the formation of a protein complex called the inflammasome, in which activated caspases cleave the N-terminus of gasdermin, forming membrane perforations that cause cell rupture, followed by leakage of cellular contents and the release of inflammatory mediators.
[0106] Non-inflammatory apoptosis and inflammatory pyroptosis do not occur independently but are mutually influential. The determining factor between apoptosis and pyroptosis is the difference in the formation of pores in the plasma membrane and the outer mitochondrial membrane.
[0107] Currently, there are two major pathways for apoptosis and pyroptosis. In apoptosis, the aforementioned BCL-2-related proteins perforate the outer mitochondrial membrane, and gasdermin E perforates both the outer mitochondrial membrane and the plasma membrane. In pyroptosis, gasdermin D perforates the plasma membrane, and gasdermin E perforates the plasma membrane.
[0108] The N-terminus of gasdermin family proteins cleaved by caspases is positively charged, and so they are attracted to negatively charged acidic phospholipids in the cell membrane and the outer mitochondrial membrane, where they aggregate and form pores.
[0109] Gasdermin D is primarily involved in the formation of pores in the cell membrane, and it has been reported that inactivation of gasdermin D causes cells to switch from pyroptosis to apoptosis.
[0110] [2-4] Function of extracellular vesicles (EVs) Almost all living cells release extracellular vesicles (EVs) to transmit messages between cells. EVs are a collective term for vesicles made of lipid bilayer membranes. EVs contain functional molecules such as proteins and miRNAs, and various EVs of different origins exist in high density in the body fluids of multicellular organisms.
[0111] While biological membranes have a negative potential, EVs, which are made of the same phospholipids, also have a negative charge, and normally cannot approach biological membranes. Positively charged cationic liposomes are often used in artificial drug delivery systems (DDS), but loss of cell membrane potential can easily cause cell death, and it is difficult to completely eliminate cytotoxicity with conventional liposomes.
[0112] Lilac-01EV is a negatively charged vesicle with a diameter of 200 nm or less, and a composition containing the culture medium of Bacillus coagulans lilac-01 is used as a supplement, and its safety has been recognized and it has a long history of consumption. 9 The presence of lilac-01EV at more than 100 cells / ml has been confirmed.
[0113] It is thought that arginine and peptides in the culture medium form a basic gel in the gastrointestinal tract, forming a counterion condensation layer around negatively charged EVs. The basic gel may contain not only arginine or arginine-rich peptides, but also a basic polymer gel. Such a basic gel forms a positively charged counterion condensation layer around negatively charged EVs, allowing them to easily approach negatively charged biomembranes and deliver EVs over a wide area of the gastrointestinal tract.
[0114] EVs are taken up into cells from the gastrointestinal epithelium by phagocytosis or macropinocytosis (pinocytosis) along with a condensed layer of counterions.
[0115] It is believed that EV membrane components fuse with the cell membrane of the host cell, and arginine is metabolized via different pathways depending on the state of the cell. In an inflammatory state, nitric oxide synthase is induced as an immune response, increasing NO production, which in turn actively takes up arginine from outside the cell. In an anti-inflammatory state, arginase-1 expressed by macrophages metabolizes arginine to produce ornithine. As a result, cells are constantly in a state of arginine deficiency.
[0116] [2-5] Effect of counterion condensation layer While CL is an essential phospholipid for the mitochondrial membrane, its strong negative charge also has adverse effects. Anticardiolipin antibodies have a strong affinity for the negative charge of CL, 2 Glycoprotein I (β 2 The antigenic determinant is β 2 CL is located on the GPI molecule and is not antigenic in itself.
[0117] When a positively charged counterion condensed layer exists, the negative charge of CL is cancelled out, so β 2 It is believed that binding to GPI can be inhibited, and antiphospholipid syndrome can be prevented by ingesting lilac-01EV, applying it to the skin, spraying it into the nasal cavity, inhaling it into the alveoli, dropping it into the eyes, injecting it, etc.
[0118] Furthermore, as mentioned above, the use of arginine in the counter ion condensation layer improves intracellular transport.
[0119] [2-6] Effect of CL / PG on the cell membrane GSDRM proteins produced within cells are separated by caspases activated by inflammasomes, and the N-terminus of GSDRM forms a polymer to form GSDRM pores, which then form holes in the cell membrane.
[0120] Gasdermin D is cleaved by caspases 1, 4, and 5, resulting in pyroptosis, an inflammatory cell death. Gasdermin E is cleaved by caspase 3, resulting in the formation of pores in the outer mitochondrial membrane or the plasma membrane, leading to apoptosis or pyroptosis. In both cases, gasdermins attack peroxidized unsaturated fatty acids in acidic phospholipids to form pores. Caspases 4 and 5 are activated by LPS and are referred to as the non-canonical inflammasome pathway.
[0121] Cell membranes contain little CL, and acidic phospholipids such as phosphatidylserine (PS), phosphatidylinositol (PI), and phosphatidic acid (PA) are present. When the phospholipids that make up the cell membrane are peroxidized, the fatty acids are cleaved, generating oxidized phospholipids that become more hydrophilic. Activated membrane perforation proteins, such as the N-terminal gasdermin protein, target and assemble on these oxidized phospholipids.
[0122] The cleaved N-terminus of GSDRM D forms pores in the cell membrane, inducing pyroptosis. Meanwhile, membrane repair mechanisms such as the endosomal sorting complex (ESCRT) are known. It has been reported that binding of negatively charged free CL to the positively charged N-terminus of GSDRM D inhibits pyroptosis.
[0123] It is thought that the CL / PG of orally ingested lilac-01EV reaches the cell membrane and repairs the phospholipid membrane.
[0124] It has been reported that the introduction of CL / PG into the cell membrane significantly improves the stability of the cell membrane. Furthermore, because lilac-01EV is made up of more than 80% saturated fatty acids, peroxidation of phospholipids is unlikely to occur, which is thought to inhibit the formation of gas dermone pores.
[0125] [2-7] Function of CL / PG in mitochondria CL is known to bind to proteins in various organelles, including mitochondria, and contribute to maintaining their activity. It has been reported that the addition of CL restores the activity of the mitochondrial electron transport chain. This suggests that a mechanism exists whereby CL fused to the plasma membrane is taken up by mitochondria in the cytoplasm. In fact, enhancement of mitochondrial activity has also been confirmed in the present invention (Example 4).
[0126] Cl is mainly present in the inner mitochondrial membrane, but 10-20% is also present in the outer membrane. Cl distribution between the inner and outer membranes is bidirectionally regulated by the membrane-bound enzyme phospholipid transfer protein (PLS).
[0127] When the inventors analyzed the phospholipids of lilac-01EV, they found that the total of PG and CL was 30% by mass or more, and the fatty acids in the acyl groups of CL were mainly odd-numbered saturated fatty acids of C15:0 and C17:0.
[0128] CL transported into cells by EVs is transferred from the outer membrane to the inner membrane of mitochondria, where lyso-forms of CL are formed by acyltransferases, which then remodel them into unsaturated fatty acids.
[0129] The four acyl groups of CL are mainly composed of highly unsaturated fatty acids, such as linoleic acid (C18:2) in the heart and arachidonic acid (C20:4), docosapentaenoic acid (C22:5), and docosahexaenoic acid (C22:6) in the brain. CL remodeled in the inner mitochondrial membrane contains unsaturated fatty acids and is a target of gasdermin D and gasdermin E.
[0130] CL is formed by the association of two PG molecules, and PG is the direct raw material for CL, so ingesting not only CL but also PG is effective in maintaining mitochondrial function.
[0131] The maintenance of mitochondrial homeostasis is a factor that determines the lifespan of a cell. Mitochondrial cell death is determined by (1) cellular stresses such as reactive oxygen species (ROS), DNA damage, and loss of membrane potential, (2) external stresses such as pattern recognition receptors (PRRs), and (3) endoplasmic reticulum stress due to the accumulation of mutant proteins.
[0132] Reactive oxygen species (ROS) are generated in mitochondria when ATP is produced, and the stress is averaged out by mitochondrial division and fusion, and weakened mitochondria undergo autophagy (mitophagy) to maintain their activity. However, if stress accumulates throughout the mitochondria, apoptosis occurs.
[0133] [2-8] Effect of Lilac-01EV In experiments using microglia, Lilac-01EV was absorbed by microglial cells and demonstrated a cytoprotective effect, with culture medium and those containing arginine exhibiting even greater cytoprotective effects. This suggests that CL taken up into the cytoplasm may repair defects in the cell membrane that cause pyroptosis. It was also confirmed to have the effect of increasing the total mitochondrial area (Example 4), and that after being taken up into the cell membrane, it reaches the inner mitochondrial membrane and contributes to improving mitochondrial content. These effects suggest that suppressing pyroptosis in macrophages may improve inflammatory conditions in humans and animals.
[0134] [3] Mechanism of onset of the target disease and the effect of lilac-01EV Next, the mechanism of onset of the target disease and the effect of lilac-01EV will be specifically explained.
[0135] [3-1] Improving cognitive function by increasing amyloid-β uptake by microglia The present inventors confirmed that amyloid-β is taken up by microglia by avoiding microglial pyroptosis (Example 1). Although several pathways for amyloid-β removal from the brain have been identified, microglia are known to be involved in the removal of insoluble and deposited amyloid-β, and are known to enzymatically degrade amyloid-β.
[0136] As we age, the number of inflammatory microglia increases in the brain, and inflammatory cytokines in the central nervous system increase chronically. Meanwhile, pyroptosis reduces the phagocytic activity of microglia. By taking lilac-01EV, microglia become anti-inflammatory and phagocytose amyloid beta. This increases their longevity, activity, and ability to maintain phagocytic activity for a long period of time, enhancing their ability to process amyloid beta, and is expected to have a significant effect on improving cognitive function.
[0137] [3-2] Chronic inflammation associated with aging and the effects of lilac-01EV Aging is the decline of the body's physiological functions, and progresses as senescent cells accumulate. The physical changes that occur with aging are not uniform for each individual, but are strongly influenced by lifestyle and the environment. The accumulation of reactive oxygen species (ROS) is thought to be the main cause of increased inflammatory responses, and the largest source of ROS is the mitochondria.
[0138] Mitochondria contain mitochondrial DNA (mtDNA) that is independent of nuclear DNA (nDNA). Because they are close to the source of ROS, mutations occur much faster than with nDNA, and mtDNA mutations accumulate with age. There are hundreds of mitochondria in a single cell, and they undergo repeated fusion and division, causing mutations that accumulate in mtDNA to spread to surrounding mtDNA. The presence of different mtDNA within a cell is called heteroplasmy, and it causes a decrease in ATP production capacity and an increase in ROS generation.
[0139] The accumulation of mtDNA mutations affects the aging of all tissues, including the brain, heart, skeletal muscle, kidneys, and endocrine system, which are organs that consume large amounts of energy. It is thought to be particularly involved in visual impairment, hearing loss, movement disorders, dementia, cardiovascular disease, arteriosclerosis, muscle weakness, kidney dysfunction, endocrine disorders including diabetes, and alveolar inflammation.
[0140] Senescent cells accumulate during aging and disease, but their death results in a certain degree of recovery for the whole organism. Senescent cells are eliminated by non-inflammatory apoptosis, but in chronic inflammatory conditions, the continuous release of inflammatory substances by macrophage pyroptosis accelerates aging.
[0141] Mitochondria determine the phenotype of macrophages, and they not only direct the death of inactive cells but also act as a control center for the aging and death of cells and the entire organism. Senescent cells are in a chronic inflammatory state caused by inflammatory macrophages, and are characterized by the accelerated accumulation of inflammatory mediators such as cytokines they produce. This effect is particularly pronounced in neurons and cardiomyocytes, which do not divide.
[0142] Ischemia-reperfusion (I / R) injury is a pathological process caused by the resumption of blood supply (reperfusion) to tissues after blood supply restriction, leading to cell death and organ dysfunction. I / R injury can occur in many vital organs, including the brain, heart, and kidneys. I / R increases mitochondrial load and generates large amounts of reactive oxygen species (ROS), which can lead to the constitutive occurrence of pyroptosis, resulting in tissue inflammation and organ dysfunction. Organs with high ATP demand are at particular risk. Blocking the pyroptosis pathway has been shown to reduce I / R injury in many organs, including neurons, kidneys, liver, alveoli, and retina.
[0143] Thus, mitochondrial damage has been identified as an important factor in I / R injury. Senescent cells can accumulate in multiple organs as a result of I / R injury, and cellular senescence has been reported to transform acute organ injury into chronic injury. This phenomenon, called stress-induced cellular senescence (SIPS), plays an important role in the dysfunction of multiple organs, particularly the kidney, heart, and brain.
[0144] I / R injury has been reported to be closely associated with excessive production of mitochondrial reactive oxygen species, mitochondrial calcium overload, impaired mitochondrial energy metabolism, mitophagy, mitochondrial fission, and mitochondrial fusion. The ATP production capacity of mitochondria depends on the surface area of the cristae membrane, and cardiolipin CL plays an important role in forming the cristae membrane curves that invaginate the inner mitochondrial membrane, thereby inducing mitochondrial fission / fusion.
[0145] Lilac-01EV supplies CL to mitochondria to enhance mitochondrial activity, repairs gas dermone pores, and strengthens mitochondrial activity, thereby avoiding cellular pyroptosis. This helps maintain cognitive, visual, olfactory, auditory, and motor functions, as well as urinary, respiratory, and swallowing functions, and reduces nasal congestion.
[0146] Furthermore, recent research has revealed that pyroptosis plays an important role not only in macrophages but also in epithelial cells. Skin aging is caused by endogenous factors, the same as body aging, as well as exogenous factors such as UV exposure. UV exposure causes inflammation in the dermis, accelerating skin aging. Aging and photoaging lead to atrophy of epidermal cells and a decrease in dermal fibroblasts and extracellular matrix components, resulting in skin blemishes, wrinkles, skin aging, and thinning.
[0147] Furthermore, lilac-01EV is expected to suppress inflammatory responses such as asthma by inhibiting pyroptosis in alveolar macrophages. In fact, it has been reported that PG / CL in alveolar surfactant has an anti-inflammatory effect.
[0148] Epithelial cells have a unique mechanism for pushing out dying cells while maintaining their barrier function. Pyroptosis has also been observed in epithelial cells, triggering an inflammatory response and resulting in loss of cell membrane integrity. The release of intracellular contents causes uncontrollable inflammation, impairing the barrier function and allowing the entry of extracellular foreign substances. If keratinization does not occur normally in skin epithelial cells, it can lead to skin disorders such as psoriasis, as well as atopic dermatitis and food allergies.
[0149] Lilac-01EV has been shown to have rejuvenating effects by suppressing pyroptosis and increasing mitochondrial activity in skin fibroblasts, thereby improving aging. This means that it is expected to reduce skin blemishes and wrinkles, improve skin aging, and reduce skin abnormalities such as psoriasis, atopic dermatitis, and food allergies.
[0150] [3-3] Chronic inflammation associated with obesity and the effect of lilac-01EV Obesity is a condition characterized by excessive accumulation of adipose tissue and is involved in the differentiation of macrophages throughout the body and insulin resistance. Macrophage differentiation is considered an important target of insulin resistance.
[0151] Visceral obesity is strongly associated with fatty liver disease and is known to directly induce pyroptosis in Kupffer cells, hepatic stellate cells, and hepatocytes, which express inflammasomes that cause pyroptosis, or to indirectly cause hepatocellular injury.
[0152] Insulin resistance is a phenomenon in which sensitivity to insulin decreases in peripheral tissues such as adipose tissue, skeletal muscle, and the liver due to obesity, and is a major cause of type 2 diabetes.
[0153] When insulin binds to insulin receptors in skeletal muscle and adipocytes, glucose transporters such as GLUT4 are transported onto the cell membrane, allowing glucose to be taken up into the cell. It is known that the inflammatory cytokine TNF-α, produced by adipocytes and macrophages, inhibits the translocation of GLUT4 to the cell membrane.
[0154] Furthermore, it has been reported that impaired signal transduction at the mitochondria-endoplasmic reticulum (MAM) interface has a wide range of effects on many diseases, including obesity, diabetes, and neurodegenerative diseases. Specifically, it has been reported that impaired enzymes such as phosphatidylinositol 3-kinase (PI3K) produced at MAM or impaired glucose transporters such as GLUT4 lead to insulin resistance. MAM is also involved in the activity of enzymes that regulate phospholipid metabolism, and adjusts cell membrane density through the composition ratio of PC and PE. CL levels have also been reported to be associated with heart disease, muscle disorders, autoimmune diseases, diabetes, and other conditions.
[0155] Insulin resistance is involved in non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, liver failure, viral hepatitis, and sepsis-related liver damage, and inhibiting pyroptosis in macrophages and other cells is expected to not only improve liver function, but also reduce visceral fat and triglycerides, improve swelling, and alleviate fatigue and lethargy.
[0156] The inventors have also confirmed pyroptosis in pancreatic beta cells, which are the organ that produces insulin, and believe that pyroptosis in pancreatic beta cells is the underlying cause of type 1 diabetes and progressive type 2 diabetes.
[0157] It has been reported that patients with type 2 diabetes are at increased risk of developing Alzheimer's disease, and vice versa, suggesting that Alzheimer's disease is associated with metabolic disorders in the central nervous system. In fact, it has been reported that increased insulin resistance reduces glucose uptake in neurons, leading to the accumulation of insulin and hyperphosphorylated tau.
[0158] It is thought that microglial pyroptosis leads to the production of inflammatory cytokines such as TNF-α, which leads to the accumulation of waste products such as fibrotic amyloid beta without being removed. This, combined with the stagnation of cell membrane migration of glucose transporters such as GLUT4 and dysfunction of MAM, leads to insulin resistance, which in turn leads to impaired brain function and Alzheimer's disease.
[0159] Lilac-01EV increases mitochondrial activity and suppresses pyroptosis in macrophages, which can improve the chronic inflammatory state caused by obesity, and is expected to have effects such as mitigating rising blood sugar levels, reducing visceral fat and triglycerides, improving basal metabolism, and maintaining vascular health.It is also expected to prevent the onset of Alzheimer's disease in type 2 diabetes patients.
[0160] [3-4] Chronic inflammation associated with psychological stress and the effects of lilac-01EV Psychological stress is a major risk factor for depression and anxiety disorders, but it is also associated with various stress-related disorders such as skin disorders such as alopecia areata, alopecia totalis, psoriasis, atopic dermatitis, vitiligo, and acne, as well as sleep disorders.
[0161] Brain inflammation is primarily mediated by microglia, which enter an activated state upon initial environmental stressor recognition and tend to induce sustained inflammatory responses upon subsequent exposure to additional stressors. Such a priming effect has been confirmed in the NLRP3 inflammasome, where a lowered activation threshold has been reported to amplify the production of inflammatory cytokines such as IL-1β and TNF-α.
[0162] Lilac-01EV inhibits microglial pyroptosis, making it possible to avoid chronic inflammation in the brain, and improve various stress-related diseases such as depression and anxiety disorders caused by psychological stress, alopecia areata, alopecia totalis, gray hair, psoriasis, atopic dermatitis, vitiligo, and acne. It can also improve sleep quality, maintain mental health, alleviate physical discomfort caused by stress, and improve tremors and itching in the hands and feet.
[0163] [3-5] Mechanism of Autoimmunity and the Effect of Lilac-01EV Autoimmune diseases are diseases caused by acquired immunity against autoantibodies, and a typical example is autoimmune disease against citrullinated proteins. Citrullination is a reaction in which arginine, one of the amino acids that make up proteins, is converted to citrulline by the enzyme peptidylarginine deiminase (PAD). Arginine is the most basic of the amino acids that make up proteins, and the citrullination reaction reduces the positive charge of proteins, causing significant changes in their higher-order structure, often resulting in the production of mutant proteins and the formation of antigens for autoimmune diseases.
[0164] There are five known types of PAD enzymes, and PAD4 differs from the other PAD enzymes in that it citrullinates arginyl residues on nuclear histones, thereby reducing the positive charge of the histones and weakening the electrostatic bond between the histones and DNA.
[0165] Therefore, histone citrullination leads to chromatin decondensation and the formation of NETs, which are chromatin such as DNA that neutrophils release into the environment to combat foreign microorganisms such as bacteria (see below for details).
[0166] Many autoimmune diseases are associated with PAD and increased citrullination, and it also plays an important role in tumorigenesis. It is also involved in the pathogenesis of psoriasis, rheumatoid arthritis (RA), and multiple sclerosis (MS), and similar mechanisms have been suggested to be at work in glaucoma and many collagen diseases.
[0167] Antibodies against citrullinated proteins are the most specific antibodies for RA and are used as useful diagnostic tools for early detection of RA.
[0168] PAD is also expressed in large amounts in the central nervous system, particularly in glial cells such as astrocytes and oligodendrocytes, and it has been reported that citrullinated proteins appear in large amounts in the brains of Alzheimer's disease patients. In addition to Alzheimer's disease, accumulation of citrullinated proteins and increased PAD activity have also been reported in prion disease, Parkinson's disease, and multiple sclerosis. PAD is distributed throughout the body, and the production of citrullinated proteins and autoantibodies against them has been confirmed in kidney disorders and other conditions.
[0169] Denatured proteins are eliminated when cells reach the end of their lifespan by being phagocytosed by macrophages. The accumulation of denatured proteins also causes stress on cells (endoplasmic reticulum stress), inducing apoptosis via mitochondria. When citrullinated proteins are phagocytosed by macrophages, citrulline is converted into arginine and can be reused.
[0170] Another example of autoimmunity is autoimmune diseases of the type I interferon (IFN-I) pathway. This was discovered by the fact that a high prevalence of systemic lupus erythematosus (SLE) was found in people with a specific IFN-I-dependent gene pattern, and it has now been revealed that similar expression patterns are seen in patients with Sjögren's syndrome, dermatomyositis, psoriasis, and rheumatoid arthritis. Eighty percent of SLE patients are female, and a link with the female hormone 17β-estradiol has also been suggested.
[0171] Furthermore, in human salivary gland epithelial cell lines treated with IFN-I, the expression of caspases and gasdermin D increased, and pyroptosis was accelerated upon inflammasome activation, indicating that IFN-I is central to the pathogenesis of autoimmune diseases, including Sjögren's syndrome (SS).
[0172] SS is a chronic inflammatory autoimmune disease characterized by decreased saliva and tear production, which has been reported to be caused by pyroptosis of macrophages infiltrating the salivary glands. The main symptoms of SS are xerostomia (dry mouth) and keratoconjunctivitis (dry eyes), along with difficulty swallowing, chewing, or speaking, a foreign body in the eye, and dry or burning lips, nose, and throat. It has also been associated with dryness of the gastrointestinal tract, vagina, lungs, and skin, as well as other extraglandular symptoms such as chronic fatigue, fibromyalgia, muscle pain, arthralgia, nephritis, and peripheral neuropathy.
[0173] Lilac-01EV inhibits the formation of gasdermin pores in the cell membrane and suppresses the occurrence of pyroptosis, thereby calming the inflammatory response. Furthermore, by inducing apoptosis in citrullinated cells, it is expected to completely cure autoimmune diseases.
[0174] [3-6] Mechanism of autoinflammation and the effects of lilac-01EV Autoinflammatory diseases have been treated as part of autoimmune diseases until now, but this is a newly proposed concept that includes inflammatory diseases caused by genetic abnormalities and pathologies involving innate immunity that have similar pathological conditions.
[0175] Many autoinflammatory diseases are induced by innate immune responses mediated by the pattern recognition receptor (PPR) pathway, which belongs to the NOD-like receptor (NLR) family. However, in many cases, other PRRs (such as Toll-like receptors (TLRs)) coexist, and adaptive immune responses are often involved in addition to innate immune responses. NLRs are a large family of PRRs that recognize molecules present on bacterial cell walls.
[0176] Autoinflammatory diseases are caused by mutations in protein-coding genes, and common mechanisms of caspase activation, gastrointestinal pore formation, pyroptosis, and subsequent tissue damage due to the release of inflammatory cytokines such as IL-1.
[0177] Amyotrophic lateral sclerosis (ALS) is caused by mutations in the antioxidant enzyme gene SOD1, and the abnormal protein TDP-43 has been detected. It has been reported that the SOD1 protein is released extracellularly, activating microglia and producing inflammatory cytokines such as TNF-α through pyroptosis.
[0178] Crohn's disease is thought to be caused by immune abnormalities against intestinal bacteria, with more than 30 confirmed mutations in NOD2, a type of NOD-like receptor (NLR) that acts as a natural immune factor.
[0179] Gout or pseudogout is caused by the NLRP3 inflammasome, a subfamily of NLRs, initiating a series of inflammatory responses in response to sodium urate (MSU) crystals and other substances. Similar specific inflammatory responses to particulate matter have also been reported for alum, cholesterol, amyloid beta, asbestos, and hydroxyapatite.
[0180] Macrophage pyroptosis mediated by the NLRP3 inflammasome and caspase-1 has been confirmed in Crohn's disease (CD), chronic kidney disease (CKD), type 2 diabetes, multiple sclerosis (MS), atherosclerosis, Alzheimer's disease (AD), cryopyrin-associated periodic syndrome (CAPS), and muscular dystrophy.
[0181] In addition, the phenomenon of macrophages causing excessive inflammation (pyroptosis) is known as macrophage activation syndrome (MAS), which is a significant risk factor in autoinflammatory diseases, and a massive immune response can lead to a cytokine storm (CS).
[0182] CS is an uncontrollable inflammatory response that can be classified as pathogen-induced, autoinflammatory, monogenic, or therapeutic intervention-induced. The signaling pathway leading to CS, like pyroptosis, is pattern recognition of PAMPs or DAMPs, and inflammatory cytokines can lead to tissue and organ damage and even death. While glucocorticoids are commonly used as immunosuppressive measures, current medical treatments are unable to control CS.
[0183] In CS, it is thought that suppressing pyroptosis of innate immune cells, namely macrophages, dendritic cells, and NK cells, which are the source of inflammatory cytokines, is effective.
[0184] Lilac-01EV inhibits the formation of gas dermone pores in the cell membrane, suppressing pyroptosis in macrophages and associated cells, thereby resolving inflammatory conditions. While cytokine-targeted biological agents require the development of inhibitors for each immune pathway, Lilac-01EV can suppress pyroptosis and all inflammatory cytokines with a single agent, potentially alleviating autoinflammatory diseases (Crohn's disease, gout / pseudogout, type 2 diabetes, MS, atherosclerosis, AD, CAPS, ALS, CKD, and CS).
[0185] [3-7] Death of cells other than macrophages and the effect of lilac-01EV Pyroptosis is not limited to macrophages, but has also been reported in granulocytes (neutrophils, eosinophils, basophils, mast cells), pancreatic beta cells, epithelial cells, goblet cells, and neurons.
[0186] The primary function of macrophages is non-inflammatory phagocytosis, and pyroptosis is thought to have been acquired evolutionarily late. Therefore, macrophages have a relatively mild inflammatory effect. In contrast, neutrophils can use a powerful tactic called neutrophil thrombosis.
[0187] Neutrophils are derived from bone marrow progenitor cells and are short-lived cells with a lifespan of approximately 10 hours. The phenomenon in which neutrophils release neutrophil extracellular traps (NETs) into their surroundings is called NETosis, and they trap and kill invaders, primarily bacteria. NETs are primarily composed of DNA and histones, and contain many bactericidal proteins and granules.
[0188] In addition to mitochondrial stress, neutrophil chromatin structure is relaxed by citrullination mediated by PAD4, leading to membrane perforation by gasdermin D and Ca2+ transport. 2+ It has been reported that the influx of
[0189] NETs are involved in chronic inflammatory diseases such as atherosclerosis, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and asthma, and also play a detrimental role in bacterial sepsis and are highly prominent in the sputum of cystic fibrosis patients.
[0190] Neutrophil NETOSIS appears to be insufficient to kill foreign microorganisms, and eosinophils are able to release even more potent extracellular traps to initiate an inflammatory response.
[0191] Eosinophils are even more short-lived innate immune cells than neutrophils that are primarily responsible for defense against parasites. Eosinophils are important in many chronic inflammatory diseases, especially allergic reactions such as bronchial asthma and atopic dermatitis.
[0192] Neutrophils and eosinophils are cells that are born to die and are very short-lived. During inflammation, the cells involved stimulate each other, making them prone to overreaction. In modern life, where there is less need to attack foreign bacteria and parasites, the main battlefield of granulocytes (neutrophils, eosinophils, basophils), they have become over-equipped. This type of inflammation is called type 2 inflammation, involving Th2 cells and NH cells.
[0193] Asthma is classified into eosinophilic asthma (type 2 inflammation), which is primarily caused by eosinophils, neutrophilic asthma, which is primarily caused by neutrophils, and others. Eosinophils play a key role in allergies and asthma, and are pro-inflammatory cells found in most inflammation.
[0194] Food allergies (FA) are a variety of adverse immune responses to specific food antigens, usually proteins. Scientific data on IgE-mediated FA has been accumulated through extensive clinical studies. However, in recent years, non-IgE or mixed allergies have been rapidly increasing.
[0195] Eosinophilic inflammatory syndrome (EOS) is a recently recognized allergic disease characterized by eosinophil-dominant inflammation and classified as type 2 inflammation. Eosinophilic esophagitis (EoE) is one of the types of EOS.
[0196] EoE is a food allergy that was first reported in 1977 and has been rapidly increasing in Europe, the United States, and Australia since the 1990s. EoE is strongly associated with asthma, allergic rhinitis, atopic diseases, and IgE-mediated food allergies, with the main allergens in adults being milk, wheat, eggs, and soy. When an allergen enters the body, it is known to produce two peaks: an immediate response and a delayed response. The former is an immediate response caused by IgE and mast cells, and the latter is a delayed response caused by IgG and eosinophils.
[0197] While IgE-mediated food allergies are caused by the activation of mast cells present in many tissues and organs throughout the body, EoE involves eosinophils and mast cells that are limited to the digestive tract and respiratory tract, and mouse studies have indicated that the skin may also be involved in sensitization.
[0198] In addition to EoE, eosinophilic inflammatory syndromes include eosinophilic gastroenteritis, eosinophilic sinusitis, atopic dermatitis, and allergic rhinitis (hay fever), all of which are type 2 inflammations involving eosinophils. Atopic dermatitis is a chronic skin inflammation accompanied by itching, and has been reported to be associated with the development of systemic organ inflammation.
[0199] Various biological agents have been developed for allergic diseases classified as type 2 inflammation, but they have issues such as limited effectiveness in certain immune pathways and side effects. Neutrophil nephrosis and eosinophil ethosis, which are suicide cell deaths, are also gasdermin D-dependent, operate through a mechanism similar to pyroptosis, and have been reported to be induced by macrophage pyroptosis.
[0200] Because pyroptosis is also a cause of death in cells other than macrophages, ingestion of lilac-01EV is expected to have the effect of repairing gas dermone pores in the cell membrane and suppressing pyroptosis. Furthermore, pyroptosis is not limited to the digestive tract or respiratory tract; it can occur in any cell that comes into contact with the outside world, such as epithelial cells of the skin, alveolar epithelium, nasal epithelium, and corneal epithelium. Stabilizing pyroptosis in epithelial cells and immune cells in advance by oral ingestion of lilac-01EV, as well as by applying it to the skin, spraying it into the nasal cavity, or using it as an eye drop, is thought to be effective in preventing inflammation.
[0201] [3-8] Inhibitory effect on gastrointestinal inflammation In inflammatory bowel disease (IBD), TNF-α produced by activated macrophages due to gastrointestinal inflammation plays an extremely important role. It has also been reported that TNF-α expression is high due to mild mucosal inflammation in irritable bowel syndrome (IBS).
[0202] Cytokines in the intestinal mucosa interact not only with immune cells but also with epithelial cells and stromal cells, and are involved in defense against foreign microorganisms and regeneration in the mucosal microenvironment.
[0203] All intestinal epithelial cells lining the intestinal wall divide and differentiate from intestinal epithelial stem cells present in the crypts, migrate toward the villi, and within 3-4 days undergo apoptosis at the apex of the villi, shedding into the lumen. Intestinal epithelial cells include goblet cells that produce mucus and Paneth cells that produce antimicrobial peptides, and their pyroptosis affects the homeostasis of the microenvironment.
[0204] Goblet cells in the intestinal epithelium form a mucus layer, and mucus proteins play a crucial role in maintaining intestinal homeostasis by restricting the colonization and invasion of intestinal microorganisms. When the mucus layer disappears and bacteria come into direct contact with the epithelium, ulcerative colitis (UC), characterized by chronic inflammation, and dysplasia (polyps and diverticula) develop.
[0205] Paneth cells, present in the crypts of the small intestine, are specialized cells that produce and secrete antimicrobial peptides and are essential for defense against intestinal bacterial invasion. It has been reported that pyroptosis of these cells in the small intestine impairs their essential functions and causes UC.
[0206] Similarly, in the large intestine, it has been reported that TLRs and NLRs are involved in the loss of intestinal mucosa due to pyroptosis of intestinal epithelial cells, resulting in UC and IBS.
[0207] Lilac01EV suppresses pyroptosis and inflammation, and is therefore expected to have the effect of restoring the intestinal mucosa and curing UC, IBS, and dysplasia.
[0208] In the digestion of carbohydrates, digestive enzymes in the small intestine digest the sugars down to disaccharides, which are then transported to the microvilli where the final stage of digestion, membrane digestion, takes place. Microorganisms cannot invade the microspaces formed by the microvilli of the small intestinal mucosa. When disaccharides come into contact with membrane digestive enzymes localized in the brush border membrane on the lumen-facing side of small intestinal epithelial cells, they are digested down to monosaccharides. The brush border membrane contains sodium-coupled glucose transporters (SGLTs), which actively transport monosaccharides into the cells.
[0209] However, it has been reported that the action of the inflammatory cytokine TNF by pyroptosis inhibits the function of SGLT. As a result, the monosaccharides produced by membrane digestion diffuse back to the luminal side and are rapidly fermented by enteric bacteria in the small intestine, resulting in the formation of organic acids and H 2 , CO 2 This phenomenon occurs when sensitized foods pass through the digestive tract, triggering an inflammatory response, which causes diarrhea and bloating in IBS, as well as chronic intestinal pseudo-obstruction.
[0210] Lilac-01EV suppresses inflammation, thereby inhibiting the production of inflammatory cytokines such as TNF. As a result, it normalizes malabsorption caused by glucose transporter dysfunction and prevents rapid intestinal fermentation. As a result, it can alleviate postprandial heaviness, heartburn, nausea, and bloating caused by abnormal fermentation in the small intestine. It also inhibits pyroptosis in intestinal epithelial cells, including goblet cells, and restores intestinal epithelial cells, including the mucus layer.
[0211] [3-9] Effects on aging-related muscle weakness and related diseases. Age-related muscle weakness has been thought to be the result of skeletal muscle aging. However, skeletal muscle is constantly remodeling, and motor neurons are repeatedly lost and regenerated. It has been reported that a decrease in activity in the motor brain area increases oxidative stress in motor neurons, impairing the energy metabolism of muscle fibers. Therefore, it has been shown that muscle strength can be restored with the right methods.
[0212] When motor neurons are lost, existing muscle fibers undergo regeneration to restore function, but some nerve fibers fail to regenerate with aging, resulting in a decline in muscle strength. Degeneration of the neuromuscular junction (NMJ) is thought to be a major factor in sarcopedia. Ageing has been shown to cause differences in NMJ remodeling, with the loss of fast motor units being particularly prominent. Mitochondria in this region are reduced, and dramatic changes in mitochondrial morphology at axon terminals, including cristae destruction, swelling, and the formation of megamitochondria, have been reported. A decrease in mitochondrial number and function, along with frequent morphological changes and inactivity, have been observed in many tissues, including skeletal muscle.
[0213] In skeletal muscle regeneration, engulfment of dead cells by macrophages is a critical step in tissue regeneration after injury. Many studies have used a widely used muscle regeneration model after toxic injury. In this model, proinflammatory macrophages (M1 type) first promote inflammation, which resolves between two and three days after injury, stimulating tissue repair, angiogenesis, and matrix remodeling, leading to myogenesis. This sequence of events, which leads to skeletal muscle regeneration, also includes promoting fibroblast differentiation and collagen production. While it is unclear whether the initial inflammation itself is necessary, it has been shown that its resolution is essential.
[0214] Lilac-01EV can induce an anti-inflammatory (M2) phenotype by suppressing macrophage pyroptosis. Furthermore, as shown in the Examples, several subjects reported that taking Lilac-01EV prevented them from experiencing muscle pain. This suggests that muscle pain occurs during the inflammation and repair process and is not necessarily required for the regeneration process. It is believed that myogenesis can occur during skeletal muscle regeneration without undergoing the inflammation and repair process, which is expected to contribute to strengthening skeletal muscle.
[0215] [Examples] Example 1. Establishment of a method for evaluating cytoprotective effects using primary microglia The pyroptosis-suppressing effect of EV (lilac-01EV) derived from Bacillus coagulans lilac-01 strain was evaluated using primary rat microglia.
[0216] Test Example 1-1. Measurement of microglial cell protective effect 1 Bacterial-derived EV was added to primary microglial cells, and the number of surviving cells was measured.
[0217] (1) Preparation of primary microglial cells A suspension of rat primary microglial cells was prepared using a primary microglial culture kit (SD rat, manufactured by Cosmo Bio Co., Ltd.), and then added to the wells at 100 μL / well. The cells were incubated at 37°C and 5% CO 2 The cells were cultured in an incubator for 6 hours.
[0218] (2) Preparation of Bacterial EVs The following bacterial EVs were diluted 5-, 25-, and 125-fold with medium: control (PBS added), Escherichia coli EV (ECEV, Cosmo Bio), Lactobacillus paracasei EV (LBEV, Cosmo Bio), Bacillus coagulans lilac-01 EV (lilac-01EV, Cosmo Bio), and Leuconostoc mesenteroides EV (LeuEV, Cosmo Bio). To match the concentration of the other EVs, lilac-01EV was diluted 10-fold with DPBS before dilution with medium and used as the stock solution.
[0219] (3) Measurement of viable cell count The culture medium was removed from the 96-well plate in which microglia were cultured, and the EV solution was added. 2 After culturing for 2 days in an incubator, the number of viable cells was determined from metabolic activity using a cell proliferation / cytotoxicity assay kit, Cell Counting kit-8 (CCK-8, Dojindo Laboratories). The cells were then fixed with 10% formalin, stained with Giemsa, and measured using an all-in-one fluorescence microscope (BZX-710, Keyence Corporation).
[0220] (4) Results A comparison of the number of viable microglial cells is shown in Figure 1. The bacterial-derived EVs are concentrated from left to right (dilution ratios of 125x, 25x, and 5x, respectively). As shown in Figure 1, the number of viable microglial cells decreased with increasing concentration when Escherichia coli EV (ECEV) and Lactobacillus acidophilus EV (LeuEV) were added, but the addition of lilac-01EV maintained the number of viable cells.
[0221] Test Example 1-2. Measurement of microglial cell protective effect 2 Bacterial-derived EV was added to primary microglial cells, and the amount of amyloid β uptake and the number of surviving cells were measured.
[0222] (1) Preparation of bacterial-derived EVs Bacterial-derived EVs (control (PBS added), ECEV, LBEV, lilac-01EV) were diluted with medium. To match the concentration of lilac-01EV with the other EVs, a solution diluted 10-fold with DPBS was used as the stock solution before dilution with medium.
[0223] (2) Preparation of primary microglial cells: A suspension of rat primary microglial cells was prepared using a primary microglial culture kit, and then added to the wells at 50 μL / well. The EV solution was also added, and the cells were incubated at 37°C in 5% CO. 2 The cells were cultured in an incubator for 4 days.
[0224] (3) Addition of amyloid β Amyloid β (TAMRA-Aβ(1-42), manufactured by Cosmo Bio Co., Ltd.) was prepared in the medium to a final concentration of 100 μM, and after removing the culture supernatant, 100 μL / well of the amyloid β was added. The amyloid β was incubated at 37°C and 5% CO 2 The cells were cultured in an incubator for 24 hours.
[0225] (4) Nuclear Staining The culture medium containing amyloid β was removed, and a nuclear staining solution (Hoechst 33342 Cellstain-Hoechst 33342 solution, manufactured by Dojindo Laboratories) was added. After incubation for 1 hour and staining, images were measured using a fluorescence microscope.
[0226] (5) Cell Counting Using a fluorescence microscope image analysis software (hybrid cell count analysis), the number of cells that had taken up amyloid β and the number of stained nuclei in each image were counted.
[0227] (6) Results (i) Fluorescence microscopic images of microglia after EV addition are shown (Figure 2). Microglia gradually decreased in the control (PBS-added) setting (Figure 2A). Microglia added with E. coli EV (ECEV) underwent pyroptosis, bursting, and gradually dying, eventually resulting in the death of almost all cells (Figure 2B). In contrast, none of the microglia added with the control (Figure 2A), Lactobacillus EV (LBEV, Figure 2C), or lilac-01 EV (Figure 2D) underwent pyroptosis or bursting. The number of surviving microglia added with lilac-01 EV (Figure 2D) was higher than that of E. coli EV (ECEV)-added microglia (Figure 2B), and was also higher than that of the control (Figure 2A) and Lactobacillus EV (LBEV, Figure 2C). It was shown that lilac-01EV has a protective effect on microglia cells.
[0228] (ii) Figure 3 shows a comparison of the number of viable microglial cells and the number of cells that had incorporated amyloid beta. Using image analysis software, we measured the number of viable microglial cells (Figure 3A) and the number of amyloid beta cells that had incorporated into microglial cells (Figure 3B). The results showed that the addition of E. coli EV (ECEV) reduced the number of viable cells (Figure 3A) and the number of amyloid beta cells (Figure 3B). The addition of lilac-01EV significantly increased the number of viable cells (Figure 3A) and the number of incorporated amyloid beta cells (Figure 3B). Furthermore, the addition of lilac-01EV resulted in a higher number of viable cells (Figure 3A) and a higher number of incorporated amyloid beta cells (Figure 3B) than the other lactic acid bacteria (LBEV).
[0229] These results showed that the addition of lilac-01EV has a protective effect on "microglia that retain the activity of uptake of amyloid beta" compared to EV derived from other bacteria.
[0230] Test Example 1-3 The effect of pretreatment with lilac-01EV on preventing the microglial killing action of E. coli EV (ECEV) was investigated.
[0231] (1) Preparation of primary microglial cells: A suspension of rat primary microglial cells was prepared using a primary microglial culture kit, and then added to the wells at 50 μL / well. The cells were incubated at 37°C and 5% CO 2The cells were cultured in an incubator for 2 days.
[0232] (2) Preparation of bacterial-derived EVs Bacterial-derived EVs (control (PBS added), ECEV, lilac-01EV) were diluted with medium. To match the concentration of lilac-01EV with the other EVs, a 10-fold dilution with DPBS was used as the stock solution before dilution with medium.
[0233] (3) Culture Method The culture medium was removed from the 96-well plate in which microglia had been cultured, and lilac-01EV solution was added. The plate was then incubated at 37°C in 5% CO. 2 The cells were pretreated by culturing in an incubator for one day, after which E. coli EV (ECEV) was added and the cells were similarly cultured for one day.
[0234] The results were compared with cells cultured without pretreatment after addition of PBS, E. coli EV (ECEV), or lilac-01EV. All cells were fixed with 10% formalin, stained with Giemsa, and observed under a fluorescence microscope.
[0235] (4) Results Photographs of microglia observed under a fluorescence microscope are shown (Figure 4). Microglia added with E. coli EV (ECEV) underwent pyroptosis, bursting and dying (Figure 4B). In the wells containing microglia added with lilac-01EV (Figure 4C), the number of surviving microglia was greater than in the wells containing E. coli EV (ECEV) (Figure 4B), and the number of cells was greater than in the control (PBS added, Figure 4A).
[0236] Furthermore, in the wells containing microglia pretreated with lilac-01EV and then supplemented with E. coli EV (Figure 4D), unlike the wells containing E. coli EV (Figure 4B), the number of microglia did not decrease, and instead increased, similar to the wells cultured with lilac-01EV alone (Figure 4C). The fluorescence micrographs of the microglia were analyzed using image analysis, and the results, plotted as the total area of cell count, are shown in Figure 4E. One-way analysis of variance (one-way ANOVA) was followed by Duncan's multiple range test. In Figure 4E, different letters indicate significant differences (p<0.05).
[0237] From the above, it was shown that pretreatment with lilac-01EV is effective in preventing the action of E. coli EV to kill microglia (pyroptosis).
[0238] Test Example 1-4 Whether the N-terminus of gasdermin D (approximately 10 kDa), a substance that causes pyroptosis, is contained in the culture supernatant obtained by culturing with the addition of various EVs was investigated.
[0239] (1) Method Mercaptoethanol was added to each culture supernatant of Test Examples 1 to 3, and Western blotting was performed using an anti-Gasdermin D antibody (Affinity Biosciences).
[0240] (2) Results A gel photograph of "Gasdermin D" and "Gasdermin D N-terminus" in the culture supernatant after the addition of EV is shown (Figure 5). Figure 5A (approximately 25 kDa) shows the band of Gasdermin D, which does not cause pyroptosis by creating holes in cells, and Figure 5B (approximately 10 kDa) shows the band of "Gasdermin D N-terminus," which causes pyroptosis. The band of "Gasdermin D N-terminus," the substance that causes pyroptosis, was not detected in the control (PBS-added) or lilac-01EV-added supernatants. The band of "Gasdermin D N-terminus," the substance that causes pyroptosis, was detected only in the supernatant added with E. coli EV. This confirmed that the rupture of microglia after the addition of E. coli EV was pyroptosis, demonstrating that E. coli EV causes pyroptosis but lilac-01EV does not.
[0241] Example 2 The correlation between the pyroptosis-suppressing effect of lilac-01EV and zeta potential was evaluated using rat primary microglia.
[0242] Test Example 2-1 Various types of lilac-01EV were prepared, and the number of nanoparticles and the average particle size were measured, and photographs were taken with an electron microscope.
[0243] (1) Purification and Measurement of Various Lilac-01EVs The lilac-01 strain was inoculated into medium and cultured for 24 hours. The medium was then centrifuged and the supernatant was filtered (0.2 μm). The filtrate was ultrafiltered using a centrifugal filter unit (Amicon Ultra-0.5, 100K), washed and concentrated three times with PBS, and then filtered (0.2 μm) to obtain the EV solution. The particle size and number of nanoparticles were measured (Nanosite, Malvern, LM10V-HS). Similarly, EVs were purified from medium alone and from a culture medium supplemented with arginine. Electron microscopy was performed using a transmission electron microscope (Hitachi, H7600). Images of the lilac-01 strain producing lilac-01EV were taken using a scanning electron microscope (JEOL, JSM7400F).
[0244] (2) Results An example of particle size distribution measured by NanoSite (Figure 6(1)) is shown, along with an electron microscope photograph of lilac-01EV (Figure 6(2): 200,000 magnification), and an electron microscope photograph of the lilac-01 strain producing lilac-01EV (Figure 6(3): 20,000 magnification). The average particle diameter of lilac-01EV measured by NanoSite was 120-129 nm, and the number was 2.5-2.9 × 10 11 The concentration of lilac-01EV was 10 ...
[0245] Test Example 2-2 The effects of various lilac-01EV purified in Test Example 2-1 were evaluated using the number of viable primary microglia cells.
[0246] (1) Preparation of primary microglial cells: A suspension of rat primary microglial cells was prepared using a primary microglial culture kit, and then added to the wells at 100 μL / well. The cells were incubated at 37°C in 5% CO.2 The cells were cultured in an incubator for 6 hours.
[0247] (2) Controls, positive control, and negative control used PBS was added as a control, Escherichia coli EV (ECEV, manufactured by Cosmo Bio) was added as a negative control, and lilac-01EV (reagent, manufactured by Cosmo Bio) was used as a positive control.
[0248] (3) Measurement of viable cell count The culture medium was removed from the 96-well plate in which microglia were cultured, and the EV solution was added. The plate was then incubated at 37°C and 5% CO 2 The cells were cultured in an incubator for 2 days, after which they were measured using the cell proliferation / cytotoxicity assay kit CCK-8.
[0249] (4) Results The difference in the effect of lilac-01EV on the culture medium and the addition of arginine was shown (Figure 7). The negative control, Escherichia coli EV (ECEV), reduced the number of viable microglial cells compared to the control (PBS addition), while the positive control, lilac-01EV (Cosmo Bio), increased the number of viable cells (Figure 7, dotted line).
[0250] The number of viable cells in "EV with medium only" was similar to that of the "control (PBS added)." The number of viable microglia was higher in "lilac-01EV purified from culture medium" than in "EV with medium only," confirming that lilac-01EV increases the number of viable microglia (Figure 7, dashed line).
[0251] Furthermore, the number of viable cells was higher when "lilac-01EV purified from culture medium" prepared in Test Example 2-1 was added than when "lilac-01EV (manufactured by Cosmo Bio Co., Ltd.)" was added (solid line in Figure 7). The effect of adding arginine was also demonstrated, as the number of viable cells was higher when "lilac-01EV purified after adding arginine to the culture medium" was added than when "lilac-01EV purified without adding arginine" (solid line in Figure 7).
[0252] The particle size (Z-average particle size) of Lilac-01EV was also measured using dynamic light scattering (DLS) (measured in a glass cell with parameters of sample refractive index 1.450, absorptivity 0.001, dispersion medium (water) temperature 25°C, viscosity 0.8872 cP, refractive index 1.330). The size was 110.6 nm for "Lilac-01EV without added arginine," and 94.6 nm for "Lilac-01EV with added arginine." It is speculated that smaller particle sizes are more likely to approach cells and be susceptible to pinocytosis by microglial cells, resulting in an increased number of surviving microglial cells.
[0253] Test Example 2-3 The zeta potential of various EVs was measured, and the relationship with the number of viable microglial cells was investigated.
[0254] (1) Method The number of nanoparticles in the various EV solutions used in Test 2-1 and Example 1 was adjusted to the same concentration with Dulbecco's phosphate-buffered saline (DPBS, no calcium, no magnesium (manufactured by Sartorius Japan)), and then the zeta potential was measured (Zetasizer Nano Z, manufactured by Malvern Panalytical). Measurement was performed using a disposable cell, and the parameters were: sample refractive index 1.590, absorptivity 0.001, dispersion medium (water) temperature 25°C, viscosity 0.8872 cP, refractive index 1.330, and dielectric constant 78.5. The metabolic activity value (CCK-8, 450 nm) from Example 1 was used to count viable microglial cells.
[0255] (2) Results of various EVs * When the relationship between the number of viable microglial cells and the zeta potential was investigated, there was a correlation between the number of viable microglial cells and the zeta potential, with a lower zeta potential indicating a higher number of viable microglial cells (Figure 8, R 2 = 0.95). The effect of arginine was demonstrated by the fact that "lilac-01EV with arginine added to the culture solution" had a lower zeta potential than "lilac-01EV without arginine." *: Cosmo Bio Co., Ltd.'s Escherichia coli EV (ECEV), Lactic acid bacteria EV (LeuEV), Lactic acid bacteria EV (LBEV), lilac-01EV, "lilac-01 culture solution EV" and "lilac-01 culture solution EV + arginine" purified in Test Example 2-1.
[0256] Example 3 The effect of lilac-01EV after drying was evaluated.
[0257] Test Example 3-1 (1) Method "lilac-01EV purified by mixing lilac-01 culture solution with a dry substrate" and "lilac-01EV purified by mixing lilac-01 culture solution with a dry substrate, drying, and then purifying" were prepared, and the number of surviving primary microglia was examined in the same manner as in Test Example 2-2.
[0258] (2) Results The graph below shows the relationship between various lilac-01EV and the number of viable cells (Figure 9). The negative control E. coli EV (ECEV) reduced the number of viable microglial cells compared to the control (PBS added), while the positive control lilac-01EV (Cosmo Bio) increased the number of viable cells (Figure 9: dotted line).
[0259] The number of viable microglial cells in "EV on dry substrate" was similar to that of the "control (with PBS)." The number of viable microglial cells was higher in "EV purified after mixing lilac-01 culture medium with dry substrate" than in "EV on dry substrate," confirming that lilac-01EV increases the number of viable microglial cells (Figure 9: solid line).
[0260] Furthermore, the number of viable cells in "EV purified after mixing lilac-01 culture medium with the dried substrate" and "EV purified after mixing lilac-01 culture medium with the dried substrate and drying" was similar, indicating that the effects of lilac-01 EV are maintained even after drying (Figure 9: solid line).
[0261] Test Example 3-2 (1) Method Lipids were extracted from lilac-01EV purified by ultrafiltration from the culture medium and the dried product of the culture medium by the Folch method, and phospholipids were analyzed by HPLC-ELSD (Softa 300S (TELEDTNE ISCO)).
[0262] (2) Results The number of EVs measured at the nanosite was 1.2 × 10 12 particles / mL and 2.8 x 10 12The concentration was 1000particles / mL. The phospholipids (PG + CL) of Lilac-01EV purified from the culture medium accounted for 87% of the total glycerophospholipids, while the phospholipids (PG + CL) of Lilac-01EV purified from the dried product accounted for 92% of the total glycerophospholipids, indicating that the number of EVs and the phospholipids (PG + CL) were not affected by drying. Furthermore, the same sample was used to analyze the odd-chain saturated fatty acids of the PGs constituting the CLs of Lilac-01EV (Table 1). The fatty acid composition shown in Table 1 was analyzed using Analyst software (API-3200, Sciex) in multiple reaction monitoring (MRM) mode. As shown in Table 1, most (approximately 80%) of the PGs in Lilac-01EV were odd-chain saturated fatty acids.
[0263]
[0264] Test Example 3-3 (1) Method Approximately 50 healthy male and female volunteers (aged 30-80) were given a dried product of lilac-01EV (approximately 0.2-0.5 g per day, 1 × 10 11 ~3 x 10 11 particles / day), and five cats and dogs were given the same dried material (approximately 0.02-0.05 g per day, 1 × 10 10 ~3 x 10 10 They were asked to take the drug (1000mg / day) and then share their impressions after one to six months.
[0265] (2) Comments from volunteers (i) Anti-aging: My blemishes have lightened and decreased in size. One blemish has disappeared. Makeup goes on better. The calluses on my knees have fallen off. My skin is smoother. My skin is more radiant. My skin tone has become one tone lighter. My foot pain has decreased. My heels are less dry than usual. My head and body feel refreshed and in good condition. My pores have closed. My complexion has improved. My hearing has improved. My gums are in better condition. My chapped skin and rough heels have become smooth. My knee pain has disappeared. My warts have gone away. My presbyopia has improved. (ii) Anti-allergy: My nose is no longer runny. I sneeze less. I no longer get sores inside my nose. I no longer have sudden watery runny nose and sneezing. My chronic rhinitis has improved and I no longer need to take rhinitis medicine. My asthma attacks improved. My allergic cough symptoms improved. I no longer had alder and birch pollen allergy symptoms, even without taking medication. My cedar pollen allergy symptoms significantly improved. My house dust allergy symptoms improved. I can now eat foods that I couldn't eat due to cross-reactions with pollen allergies. My birch pollen allergy symptoms completely disappeared. (iii) Digestive tract improvement: My stomach is in good condition and I no longer have diarrhea. My stool is more regular. Stool no longer sticks to the toilet. My stomach no longer rumbles when I eat. The discomfort and dull pain in my stomach when I eat wheat and dairy products has decreased. I no longer suffer from summer fatigue-related diarrhea. I have recovered from decades of diarrhea and now have well-formed stool. Bleeding due to IBS has improved. I am no longer constipated and have a bowel movement every day. My morning bowel movements are smooth and I feel good. I no longer have stomach aches. I am glad that I have regular bowel movements every morning when I wake up. I feel like I am producing less gas. I no longer have diarrhea or constipation, and I feel much better. My stomach is feeling much better! I have less diarrhea and I'm not constipated. (iv) Maintaining homeostasis: My body feels warm. My nose is clearer. I no longer have nosebleeds. The bags under my eyes have disappeared. My hands and feet are no longer cold. I'm urinating more and the swelling has decreased. I no longer have blood in my urine due to fatigue. The numbness and fatigue in my hands, which were aftereffects of a traffic accident, are fading. My lower back, which was so painful I couldn't even turn over in bed, is no longer hurting. The headaches in the back of my head caused by high blood pressure due to stress have subsided. I no longer get hangovers, even when I drink too much alcohol. The bruises I got from falling are disappearing quickly.The doctor was surprised to see that the traces of hemorrhage and accumulated fluid in my retina suddenly disappeared. I feel less tired. My HbH1c dropped by 0.2, even though I haven't lost any weight. I feel like my eyes are focusing more clearly. My myopia has improved. I feel refreshed. My reflexes have improved. Since I started taking lilac-01EV, my cholesterol and thyroid levels have not risen. My tendency to be anemic has improved. My menstrual irregularities have improved. My foot odor has decreased. My persistent mouth ulcers have recently started to heal. I'm really grateful for the reduced pain in my lower back, and they seem to heal faster. I no longer get muscle pain even after strenuous exercise. I used to have trouble sleeping, but now I can sleep deeply and soundly. The quality of my sleep has improved. Even if I wake up multiple times in the middle of the night, I can go back to sleep afterwards. My mouth ulcers have improved. My mind and body feel clearer and I feel better. The pain from my shoulder joint inflammation has subsided. My skin is firmer and my body feels lighter. I haven't had any post-shingles neuralgia recently. My leg joint pain has subsided. My hemoglobin A1C has gradually dropped from 7.0 to 6.3. Sudden spikes in blood sugar even after eating ice cream have been alleviated. My migraines have improved. My blood pressure has stabilized. My eye strain has decreased and my brain has become more active. My psoriasis is gradually improving. My blood pressure has returned to normal, so I stopped taking medication (blood pressure went from 150-160 / 100-110 to 130-140 / 90-100). I no longer get headaches. I no longer get hangovers. My wounds are healing quickly. I feel less dizzy. I wake up feeling refreshed. I feel less fatigued. My hot flashes are subsiding. I'm less likely to catch a cold and I feel great. I can sleep deeply and wake up feeling refreshed. I have fewer headaches. I feel better both physically and mentally. The pain and itching from my psoriasis and pachyderma have improved. My head feels clearer and more organized. I suffer from alopecia, but some hair is growing back. I went to a chiropractor and was told I've gained muscle. I've gained muscle in my legs and hips. My hyperthyroidism has improved, so I've stopped taking medication. My headaches have clearly decreased, so I've stopped taking medication. My varicose veins are improving.
[0266] (3) Condition of cats and dogs and comments from their owners (i) Anti-aging: The brown tears that had been coming out of the left eye for several months have stopped (cat). (ii) Digestive tract improvement: The chronic diarrhea that had been bothering the cat for years has stopped (cat). When the nursing mother cat ingested the product, her kittens no longer had diarrhea. The feces no longer smelled bad (cat). The diarrhea of a cat with IBD has been cured. The strong stool odor has suddenly subsided, and the kittens now have excellent feces every day. Until recently, the cat would suddenly experience loose bowels about once a week, but now the diarrhea and vomiting have stopped (cat). The cat's stomach upset has almost completely disappeared, and it has gained a little weight (cat). (iii) Homeostasis: A cat with no appetite due to feline hemoplasmosis is showing signs of recovery from gingivostomatitis. The redness of the gingivostomatitis has improved. The redness at the site where the gingivostomatitis was removed is fading. A cat with severe gingivostomatitis no longer drools like strings. It also no longer hurts when eating (Figure 10, A: before taking the medicine, B: one month after taking the medicine, arrow: string-like drool). It seems to be working on a cat with renal failure. An elderly cat's creatinine level dropped (after about one month of taking the medicine, the level dropped from 3.0 to 2.6). The white blood cell count, which had remained high for a long time, suddenly fell within the normal range (cat). (iv) Anti-allergy: A dog that had been sneezing and suffering from a runny nose due to allergies stopped producing runny noses within 2-3 days and its breathing became calmer. A dog that was itchy due to allergies seemed to itch a little less.
[0267] Example 4 The effect of lilac-01EV on activating cellular mitochondria was evaluated.
[0268] Test Example 4-1 (1) Method Aged human fibroblasts (S-HDF) were incubated at 37°C and 5% CO while the medium was replaced with PBS (control) and lilac-01EV-supplemented medium. 2 The cells were cultured in an incubator, and after 22 days, mitochondrial activity was measured (MT-1 mitochondrial membrane potential detection kit, manufactured by Dojindo Laboratories), and the nuclei were stained and photographed under a microscope.
[0269] (2) Results Cell images and activity graphs are shown below (Figure 11). In cells with added lilac-01EV (Figure 11B), the cell shape (white frame in the figure) became elongated (indicating rejuvenation of the cells) compared to the control (PBS added, Figure 11A), the number of cells in the well (nuclei: blue) increased (Figure 11E), and the area (Figure 11C) and brightness (Figure 11D) of mitochondria (red) also increased, confirming that the addition of lilac-01EV increased mitochondrial activity.
[0270] Example 5 Bacillus coagulans (Weizmannia coagulans) standard strain NBRC 12583 T The phospholipid composition and zeta potential of EVs were similarly evaluated.
[0271] Test Example 5-1 (1) Method Culture was performed in the same manner as in Test Example 2-1, and EVs were purified. The obtained EVs were analyzed for phospholipids in the same manner as in Test Example 3-2. Zeta potential was also measured in the same manner as in Test Example 2-3.
[0272] (2) Results The phospholipids were PG: 199 μg / mg of total lipids, CL: 199 μg / mg of total lipids. Since no other glycerophospholipids were detected among the phospholipids constituting the membrane of extracellular vesicles, PG + CL = 100%. The zeta potential was -17.5 mV.
Claims
1. A composition for maintaining or improving immune function, containing an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol account for 30% by mass or more of the total glycerophospholipids constituting the membrane.
2. A composition for anti-aging, anti-allergy, gastrointestinal improvement, or homeostasis maintenance, containing an effective amount of extracellular vesicles in which cardiolipin and / or phosphatidylglycerol account for 30% by mass or more of the total glycerophospholipids constituting the membrane.
3. The daily intake of the extracellular vesicles is 10 9 The composition of claim 1 or 2, wherein the number of the hydroxybenzoates is 1 or more.
4. A composition described in claim 1 or 2, characterized in that 50% or more of the cardiolipin (CL) and / or phosphatidylglycerol (PG) has an odd-chain saturated fatty acid acyl group in the side chain.
5. The composition according to claim 1 or 2, wherein the extracellular vesicles have a zeta potential of -10 mV or less in Ca- and Mg-free Dulbecco's phosphate buffered saline (DPBS).
6. A composition according to claim 1 or 2, characterized in that it further contains a composition or a basic gel suspension containing arginine or an arginine-rich peptide or protein.
7. The composition according to claim 1 or 2, characterized in that the immune dysfunction is a chronic inflammatory disease, a neurodegenerative disease, an autoimmune disease, an autoinflammatory disease, or a type 2 inflammatory disease.
8. The composition according to claim 1 or 2, wherein the extracellular vesicles are produced by Bacillus coagulans (Weizmannia coagulans) lilac-01 strain (accession number: NITE P-01102).
